aspirin and Diabetic Angiopathies studies

Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.

Diabetic Angiopathies: VASCULAR DISEASES that are associated with DIABETES MELLITUS.

Research Excerpts

Excerpt	Relevance	Reference
" None of the aspirin doses had a significant impact upon BMI, blood pressure, lipid parameters, insulin sensitivity (HOMA), FRAP, TAOS, GSH, endothelial function, glycaemic control (fructosamine) or inflammation (sVCAM-1 and HsCRP)."	9.19	Aspirin in type 2 diabetes, a randomised controlled study: effect of different doses on inflammation, oxidative stress, insulin resistance and endothelial function. ( Cummings, MH; Laight, DW; Raghavan, RP, 2014)
"This is a post-hoc analysis derived from patients (n = 79) enrolled in a prospective, randomized, double-blind, double-dummy, crossover study comparing cilostazol with placebo in stable coronary artery disease patients on aspirin and clopidogrel therapy."	9.17	Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status. ( Angiolillo, DJ; Capodanno, D; Capranzano, P; Darlington, A; Desai, B; Dharmashankar, K; Ferreiro, JL; Rollini, F; Tello-Montoliu, A; Ueno, M, 2013)
"In a population of diabetic patients with coronary artery disease and a high risk of time-dependent aspirin resistance, aspirin divided twice per day can significantly decrease the rate of biological loss of efficacy at trough level."	9.16	Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease. ( Bal dit Sollier, C; Dillinger, JG; Drissa, A; Drouet, L; Henry, P; Logeart, D; Manzo Silberman, S; Sideris, G; Voicu, S, 2012)
"Aspirin dosing regimens are associated with different pharmacodynamic effects in platelets from T2DM patients and stable coronary artery disease, with a twice-daily, low-dose aspirin administration resulting in greater platelet inhibition than once-daily administration as assessed by aspirin-sensitive assays and a dose-dependent effect on serum TXB(2) levels."	9.15	Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. ( Angiolillo, DJ; Bass, TA; Capodanno, D; Capranzano, P; Darlington, A; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Patel, A; Seecheran, N; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2011)
"The aim of this pilot study was to compare the effect of two different regimens of aspirin dosage on platelet of coronary artery disease (CAD) diabetic patients."	9.14	Antiplatelet effect of once- or twice-daily aspirin dosage in stable coronary artery disease patients with diabetes. ( Abderazek, F; Addad, F; Chakroun, T; Chouchene, S; Dridi, Z; Elalamy, I; Gamra, H; Gerotziafas, GT; Hassine, M; Hatmi, M, 2010)
"Although cilostazol has reduced the extent of neointimal hyperplasia and restenosis in patients after bare-metal stent implantation, it is not known whether this effect occurs after DES implantation in diabetic patients."	9.13	Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im ( Cho, YH; Choi, SW; Chun, KJ; Hong, MK; Kim, HS; Kim, JH; Kim, YH; Ko, JK; Lee, CW; Lee, JH; Lee, NH; Lee, SW; Park, DW; Park, JH; Park, SJ; Park, SW; Seong, IW; Yun, SC, 2008)
"A meta-analysis to investigate the effects of aspirin for the prevention of cardiovascular disease in diabetes mellitus."	9.05	Aspirin for primary prevention of cardiovascular outcomes in diabetes mellitus: An updated systematic review and meta-analysis. ( Ali, F; Kaluski, E; Khan, MU; Khan, SU; Krasuski, RA; Lone, AN; Mookadam, F; Shahzeb Khan, M; Talluri, S; Ul Abideen Asad, Z, 2020)
"The benefits of aspirin therapy in reducing the subsequent risk of myocardial infarction, stroke and death is well documented in individuals with cardiovascular disease including those with diabetes mellitus (DM)."	8.85	Aspirin therapy and primary prevention of cardiovascular disease in diabetes mellitus. ( Soran, H; Williams, S; Younis, N, 2009)
" The aim of this study was to perform serial pharmacodynamic assessments of prasugrel with high-dose clopidogrel in patients with DM."	6.76	A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. ( Angiolillo, DJ; Badimon, JJ; Baker, BA; Effron, MB; Frelinger, AL; Jakubowski, JA; Michelson, AD; Ojeh, CK; Saucedo, JF; Zhu, B, 2011)
"The primary outcome was restenosis documented by magnetic resonance (MR) angiography or duplex imaging at 12 months."	6.76	Batroxobin plus aspirin reduces restenosis after angioplasty for arterial occlusive disease in diabetic patients with lower-limb ischemia. ( Cheng, YS; Li, MH; Liu, F; Tan, HQ; Wang, J; Wang, JB; Zhao, JG; Zhu, YQ, 2011)
"Patients with type 2 diabetes mellitus (T2DM) have reduced platelet inhibition compared with non-diabetics following P2Y(12) receptor blockade."	6.73	A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. ( Angiolillo, DJ; Aslam, M; Bass, TA; Box, LC; Capranzano, P; Charlton, RK; Desai, B; Goto, S; Guzman, LA; Shoemaker, SB; Suzuki, Y; Zenni, MM, 2008)
"Fibrinogen levels were elevated in T2DM (p< 0."	5.40	The influence of type 2 diabetes on fibrin clot properties in patients with coronary artery disease. ( Ajjan, RA; Grant, PJ; Grove, EL; Hvas, AM; Kristensen, SD; Kurdee, Z; Larsen, SB; Neergaard-Petersen, S; Phoenix, F, 2014)
"Aspirin was not associated with significant mortality benefit in diabetes sufferers (95% CI 0."	5.35	Aspirin and mortality in patients with diabetes sustaining acute coronary syndrome. ( Abbas, A; Barth, JH; Cubbon, RM; Das, R; Gale, CP; Grant, PJ; Hall, AS; Kearney, MT; Morrell, C; Rajwani, A, 2008)
"Muscle infarction is a rare complication in patients with diabetes mellitus, probably because of the rich vascular supply of this tissue."	5.30	Enhanced platelet aggregation, high homocysteine level, and microvascular disease in diabetic muscle infarctions: implications for therapy. ( Levy, J; Ragatzki, P; Rajkumar, V; Sima, A, 1999)
" None of the aspirin doses had a significant impact upon BMI, blood pressure, lipid parameters, insulin sensitivity (HOMA), FRAP, TAOS, GSH, endothelial function, glycaemic control (fructosamine) or inflammation (sVCAM-1 and HsCRP)."	5.19	Aspirin in type 2 diabetes, a randomised controlled study: effect of different doses on inflammation, oxidative stress, insulin resistance and endothelial function. ( Cummings, MH; Laight, DW; Raghavan, RP, 2014)
"This is a post-hoc analysis derived from patients (n = 79) enrolled in a prospective, randomized, double-blind, double-dummy, crossover study comparing cilostazol with placebo in stable coronary artery disease patients on aspirin and clopidogrel therapy."	5.17	Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status. ( Angiolillo, DJ; Capodanno, D; Capranzano, P; Darlington, A; Desai, B; Dharmashankar, K; Ferreiro, JL; Rollini, F; Tello-Montoliu, A; Ueno, M, 2013)
"In a population of diabetic patients with coronary artery disease and a high risk of time-dependent aspirin resistance, aspirin divided twice per day can significantly decrease the rate of biological loss of efficacy at trough level."	5.16	Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease. ( Bal dit Sollier, C; Dillinger, JG; Drissa, A; Drouet, L; Henry, P; Logeart, D; Manzo Silberman, S; Sideris, G; Voicu, S, 2012)
"This study is a subanalysis of the Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) trial-a randomized, controlled, open-label trial."	5.15	Differential effect of low-dose aspirin for primary prevention of atherosclerotic events in diabetes management: a subanalysis of the JPAD trial. ( Doi, N; Jinnouchi, H; Kanauchi, M; Morimoto, T; Nakayama, M; Ogawa, H; Okada, S; Saito, Y; Sakuma, M; Soejima, H; Uemura, S; Waki, M, 2011)
"Aspirin dosing regimens are associated with different pharmacodynamic effects in platelets from T2DM patients and stable coronary artery disease, with a twice-daily, low-dose aspirin administration resulting in greater platelet inhibition than once-daily administration as assessed by aspirin-sensitive assays and a dose-dependent effect on serum TXB(2) levels."	5.15	Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. ( Angiolillo, DJ; Bass, TA; Capodanno, D; Capranzano, P; Darlington, A; Desai, B; Dharmashankar, K; Ferreiro, JL; Kodali, M; Patel, A; Seecheran, N; Tello-Montoliu, A; Tomasello, SD; Ueno, M, 2011)
"The Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) trial was a prospective, randomized, open-label trial conducted throughout Japan that enrolled 2,539 type 2 diabetic patients without a history of atherosclerotic diseases."	5.15	Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial. ( Akai, Y; Doi, N; Jinnouchi, H; Morimoto, T; Nakayama, M; Ogawa, H; Okada, S; Saito, Y; Soejima, H; Sugiyama, S; Uemura, S; Waki, M, 2011)
"The aim of this pilot study was to compare the effect of two different regimens of aspirin dosage on platelet of coronary artery disease (CAD) diabetic patients."	5.14	Antiplatelet effect of once- or twice-daily aspirin dosage in stable coronary artery disease patients with diabetes. ( Abderazek, F; Addad, F; Chakroun, T; Chouchene, S; Dridi, Z; Elalamy, I; Gamra, H; Gerotziafas, GT; Hassine, M; Hatmi, M, 2010)
"Although cilostazol has reduced the extent of neointimal hyperplasia and restenosis in patients after bare-metal stent implantation, it is not known whether this effect occurs after DES implantation in diabetic patients."	5.13	Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im ( Cho, YH; Choi, SW; Chun, KJ; Hong, MK; Kim, HS; Kim, JH; Kim, YH; Ko, JK; Lee, CW; Lee, JH; Lee, NH; Lee, SW; Park, DW; Park, JH; Park, SJ; Park, SW; Seong, IW; Yun, SC, 2008)
"Although aspirin has no significant risk on primary endpoints of cardiovascular events and bleeding outcomes in patients with diabetes compared to control, major adverse cardiovascular events (MACE) were significantly lower in the aspirin group."	5.12	Benefits and Risks Associated With Aspirin Use in Patients With Diabetes for the Primary Prevention of Cardiovascular Events and Mortality: A Meta-Analysis. ( Gu, Q; Li, X; Ma, H; Niu, H; Wang, R, 2021)
"A meta-analysis to investigate the effects of aspirin for the prevention of cardiovascular disease in diabetes mellitus."	5.05	Aspirin for primary prevention of cardiovascular outcomes in diabetes mellitus: An updated systematic review and meta-analysis. ( Ali, F; Kaluski, E; Khan, MU; Khan, SU; Krasuski, RA; Lone, AN; Mookadam, F; Shahzeb Khan, M; Talluri, S; Ul Abideen Asad, Z, 2020)
" centers, 231 male diabetic patients who had either a recent amputation for gangrene (N = 207) or active gangrene (N = 24) were randomly assigned to a group which received aspirin (325 mg t."	5.05	V.A. Cooperative Study on antiplatelet agents in diabetic patients after amputation for gangrene: III. Definitions and review of design and baseline characteristics. ( Abraira, C; Anderson, JW; Bingham, SF; Colwell, JA; Kwaan, HC, 1985)
" Laboratory and clinical data have convincingly shown the benefit of P2Y12 inhibition combined with aspirin in patients with acute coronary syndrome (ACS)/undergoing percutaneous coronary intervention (PCI)."	4.90	p2y12 receptor inhibitors in acute coronary syndromes: from the research laboratory to the clinic and vice versa. ( Alexopoulos, D, 2014)
"Aspirin (ASA) use for secondary prevention in patients with cardiovascular (CV) disease is well established through its beneficial effects on the reduction of myocardial infarction, ischemic stroke and CV mortality."	4.86	Aspirin for the prevention of cardiovascular morbidity. ( Haider, B; Kaluski, E; Klapholz, M; Maher, J; Sanchez-Ross, M; Waller, AH, 2010)
"The benefits of aspirin therapy in reducing the subsequent risk of myocardial infarction, stroke and death is well documented in individuals with cardiovascular disease including those with diabetes mellitus (DM)."	4.85	Aspirin therapy and primary prevention of cardiovascular disease in diabetes mellitus. ( Soran, H; Williams, S; Younis, N, 2009)
" The ratios of RRs comparing the benefit of aspirin among patients with diabetes compared with patients without diabetes for mortality, myocardial infarction, and ischemic stroke were 1."	4.85	Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes. ( Aggarwal, NR; Albuquerque, FN; Calvin, AD; Elamin, MB; Erwin, PJ; Fernandez-Balsells, MM; Geske, JB; Lampropulos, JF; Montori, VM; Murad, MH; Shi, Q; Smith, SA, 2009)
"Aspirin is recommended as cardiovascular disease prevention in patients with diabetes mellitus."	4.84	[Low-dose aspirin in patients with diabete melitus: risks and benefits regarding macro and microvascular complications]. ( Camargo, EG; Gross, JL; Lavinsky, J; Silveiro, SP; Weinert, LS, 2007)
" Increased leptin, dysregulation of adipocyte proteins, increased insulin resistance and C-reactive protein may be factors involved in the increased incidence of cardiovascular morbidity and mortality directly related to obesity."	4.83	Stroke prevention in diabetes and obesity. ( Govindarajan, G; Kurukulasuriya, LR; Sowers, J, 2006)
" Recommendations address diagnosis and treatment of cardiovascular risk factors (hypertension and dyslipidemia), aspirin use, screening for and treatment of coronary heart disease, and lifestyle interventions."	3.88	Cardiovascular Disease and Risk Management: Review of the American Diabetes Association Standards of Medical Care in Diabetes 2018. ( Chamberlain, JJ; Johnson, EL; Leal, S; Peterson, L; Rhinehart, AS; Shubrook, JH, 2018)
"In DM patients with coronary artery disease taking maintenance aspirin and clopidogrel therapy, impaired renal function is associated with reduced clopidogrel-induced antiplatelet effects and a greater prevalence of HPPR."	3.76	Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. ( Alfonso, F; Angiolillo, DJ; Bass, TA; Bernardo, E; Capodanno, D; Fernandez-Ortiz, A; Ferreiro, JL; Jimenez-Quevedo, P; Macaya, C; Sabaté, M; Ueno, M; Vivas, D, 2010)
"Aspirin is currently known to give inadequate protection against coronary artery disease in diabetes compared to person without it."	3.74	A study of aspirin resistance in type 2 diabetes. ( Chaudhuri, U; Chowdhury, S; Lahiri, P; Mukhopadhyay, P; Pandit, K; Singla, MK, 2008)
"Our results conclude that 10% decrease in body mass index (BMI) among overweight patients, smoking cessation, initiation to undertake a preventive treatment with low-dose aspirin, initiation to undertake or intensify blood pressure control, initiation to undertake or intensify lipidic control, and shift to biguanides among overweight patients are factors associated with significant benefits (avoided costs) which compensate for the increase in treatment costs."	3.73	[Assessment of the budgetary impact of treatment guidelines in type II diabetes mellitus in France]. ( Crainich, D; Lebrun, T; Marissal, JP; Sailly, JC, 2005)
"The Hypertension Optimal Treatment study was a large, randomized, multicenter study to determine the answers to two questions: 1) what is the optimal target blood pressure to be sought in the treatment of patients with moderate hypertension? and 2) does low dose aspirin therapy decrease morbidity and mortality in patients with hypertension? After 3."	3.70	The Hypertension Optimal Treatment Study: what did it give us? ( Bryg, RJ; Graettinger, WF, 1999)
"Ticagrelor is a P2Y12 receptor antagonist with evidence of cardiovascular event reduction in patients with acute coronary syndromes and those with a previous myocardial infarction."	2.87	Ticagrelor and the Prevention of Microvascular Complications in Diabetes Patients with Lower Extremity Arterial Disease; Rationale and Design of the Hema-Kinesis Trial. ( Chen, Q; Cho, DJ; Lee, ML; Najera, SD; Rosenson, RS, 2018)
" Clinical outcome trials evaluating primary cardiovascular disease prevention with aspirin in Type 2 diabetes may need to consider using a more frequent dosing schedule."	2.82	Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with Type 2 diabetes. ( Bethel, MA; Coleman, RL; Harrison, P; Hill, L; Holman, RR; Kennedy, I; Oulhaj, A; Sourij, H; Sun, Y; Tucker, L; White, S, 2016)
" The present study attempts to study the pharmacodynamic interactions of P."	2.79	Study of pharmacodynamic interaction of Phyllanthus emblica extract with clopidogrel and ecosprin in patients with type II diabetes mellitus. ( Fatima, N; Muralidhar, N; Pingali, U, 2014)
"The primary outcome was restenosis documented by magnetic resonance (MR) angiography or duplex imaging at 12 months."	2.76	Batroxobin plus aspirin reduces restenosis after angioplasty for arterial occlusive disease in diabetic patients with lower-limb ischemia. ( Cheng, YS; Li, MH; Liu, F; Tan, HQ; Wang, J; Wang, JB; Zhao, JG; Zhu, YQ, 2011)
" The aim of this study was to perform serial pharmacodynamic assessments of prasugrel with high-dose clopidogrel in patients with DM."	2.76	A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. ( Angiolillo, DJ; Badimon, JJ; Baker, BA; Effron, MB; Frelinger, AL; Jakubowski, JA; Michelson, AD; Ojeh, CK; Saucedo, JF; Zhu, B, 2011)
"The efficacy of low-dose aspirin in type 2 diabetes mellitus (T2DM) has been questioned."	2.76	Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications. ( Arnetz, L; Brismar, K; Hjemdahl, P; Li, N; Östenson, CG; Spectre, G, 2011)
"For the patients with newly diagnosed type 2 diabetes, additional administration of CDDP to the conventional treatment could exert beneficial effects on blood glucose controling, and lipid profile improvement and delay of arterial intima-media proliferation."	2.75	[Effect of compound danshen dripping pill on arterial intima-media thickness in patients with newly diagnosed type 2 diabetes mellitus]. ( Liu, D; Tang, JY; Yan, L, 2010)
"The primary end point was restenosis and reocclusion, which was documented by magnetic resonance angiography or duplex scanning at 12-month follow-up."	2.75	Batroxobin for prevention of restenosis in diabetic patients after infrapopliteal arterial angioplasty: a small randomized pilot trial. ( Cheng, YS; Li, MH; Liu, F; Tan, HQ; Wang, J; Wang, JB; Zhang, PL; Zhao, JG; Zhu, YQ, 2010)
" Long-term use of aspirin reduced the incidence of recurrent AMI (p = 0."	2.75	[Investigation of the effects of low dose aspirin therapy on primary and secondary prevention of cardiovascular disease]. ( Ogawa, H; Soejima, H, 2010)
"In this study of patients with type 2 diabetes, low-dose aspirin as primary prevention did not reduce the risk of cardiovascular events."	2.73	Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. ( Doi, N; Jinnouchi, H; Kanauchi, M; Morimoto, T; Nakayama, M; Ogawa, H; Saito, Y; Sugiyama, S; Uemura, S, 2008)
"Patients with type 2 diabetes mellitus (T2DM) have reduced platelet inhibition compared with non-diabetics following P2Y(12) receptor blockade."	2.73	A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. ( Angiolillo, DJ; Aslam, M; Bass, TA; Box, LC; Capranzano, P; Charlton, RK; Desai, B; Goto, S; Guzman, LA; Shoemaker, SB; Suzuki, Y; Zenni, MM, 2008)
" Increased aspirin dosing resulted in similar rates of resistance and platelet function levels between groups."	2.73	The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. ( Antonino, MJ; Bailon, O; Bliden, KP; DiChiara, J; Gurbel, PA; Hamed, MS; Singla, A; Suarez, TA; Tantry, US, 2007)
"Aspirin resistance has been often considered a guilty actor, although many mechanisms have been mistaken for true aspirin resistance, such as patient poor compliance, inadequate dosing, drug interactions, and high-platelet turnover."	2.58	Aspirin in primary prevention for patients with diabetes: Still a matter of debate. ( Bonaventura, A; Liberale, L; Montecucco, F, 2018)
" There were differences in the effect of aspirin by dosage and treatment duration on overall stroke outcomes (P for interaction for all < 0."	2.55	Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials. ( Khunti, K; Kunutsor, SK; Seidu, S, 2017)
"Obesity is a substantial cardiovascular risk factor, and recently, large trials of lifestyle and surgical (e."	2.50	Type 2 diabetes and cardiovascular disease: what next? ( Golden, SH; Joseph, JJ, 2014)
" Therefore, several new antiplatelet treatment strategies have been developed in order to optimize platelet inhibition: a) modification of dosing of commonly used agents; b) use of new agents; and c) addition of a third antiplatelet drug (triple therapy)."	2.48	Challenges and perspectives of antiplatelet therapy in patients with diabetes mellitus and coronary artery disease. ( Angiolillo, DJ; Ferreiro, JL, 2012)
" Newer aspirin dosing and scheduling, tailored at reducing the individual patient risk related to an incomplete inhibition of platelet function by a standard aspirin dose should now be defined."	2.48	Aspirin resistance, platelet turnover, and diabetic angiopathy: a 2011 update. ( Buonauro, A; Di Minno, G; Di Minno, MN; Lupoli, R; Palmieri, NM; Russolillo, A, 2012)
"Aspirin therapy was not associated with a statistically significant reduction in major cardiovascular events (relative risk [RR] 0."	2.46	Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis. ( Fu, M; Ge, J; Sun, A; Wang, K; Wu, C; Zhang, C; Zhang, P; Zhang, S; Zou, Y, 2010)
"When aspirin was compared with placebo there was no statistically significant reduction in the risk of major cardiovascular events (five studies, 9584 participants; relative risk 0."	2.45	Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. ( De Berardis, G; Graziano, G; Nicolucci, A; Pellegrini, F; Sacco, M; Strippoli, GF; Tognoni, G, 2009)
"Diabetes mellitus is commonly associated with both microvascular and macrovascular complications (coronary artery disease, cerebrovascular events, severe peripheral vascular disease, nephropathy and retinopathy)."	2.45	Diabetes, vascular complications and antiplatelet therapy: open problems. ( Cerbone, AM; Coppola, A; Di Minno, G; Macarone-Palmieri, N; Rivellese, AA; Saldalamacchia, G, 2009)
"Psoriasis is highly prevalent and is associated with skin-associated complaints as well as arthritis, depression and a lower quality of life."	2.45	Psoriasis: an opportunity to identify cardiovascular risk. ( Federman, DG; Gunderson, CG; Kirsner, RS; Prodanovich, S; Shelling, M, 2009)
"Patients with type 2 diabetes mellitus are at increased risk for macrovascular disease complications."	2.44	Preventing macrovascular complications in type 2 diabetes mellitus: glucose control and beyond. ( McGuire, DK; Stancoven, A, 2007)
"Chronic hyperglycemia is then added to these risk markers."	2.40	Multifactorial aspects of the treatment of the type II diabetic patient. ( Colwell, JA, 1997)
" The dosage of ASA in the majority of works has been about 1,000 mg daily while isolated investigations have shown good effect from doses as low as 60 mg daily."	2.38	[Acetylsalicylic acid in the treatment of arterial thromboembolytic diseases. 2. Clinical documentation]. ( Faergeman, O; Fasting, H; Husted, SE; Krusell, LR; Nielsen, HK, 1989)
"Treatment with hydroxychloroquine might not be enough to lower the cardiovascular risk significantly in diabetes patients with Sjögren syndrome."	1.72	Sjögren syndrome is a hidden contributor of macrovascular and microvascular complications in patients with type 2 diabetes. ( Leong, PY; Su, YJ; Wang, YH; Wei, JC, 2022)
"Fibrinogen levels were elevated in T2DM (p< 0."	1.40	The influence of type 2 diabetes on fibrin clot properties in patients with coronary artery disease. ( Ajjan, RA; Grant, PJ; Grove, EL; Hvas, AM; Kristensen, SD; Kurdee, Z; Larsen, SB; Neergaard-Petersen, S; Phoenix, F, 2014)
"Aspirin resistance was associated with female gender (P < 0."	1.38	The prevalence and factors associated with aspirin resistance in patients premedicated with aspirin. ( Al-Azzam, SI; Alowidi, A; Alzoubi, KH; Khabour, O; Tawalbeh, D, 2012)
"Women with CHD also had a higher rate of cerebral ischemia than did men (27."	1.36	Sex-specific differences in metabolic control, cardiovascular risk, and interventions in patients with type 2 diabetes mellitus. ( Gerhat, D; Handisurya, A; Hudson, S; Kamyar, MR; Kautzky-Willer, A; Lemmens-Gruber, R; Luger, A; Stemer, G, 2010)
"To evaluate the association between type 2 diabetes and newly reported Parkinson's disease."	1.35	Prospective cohort study of type 2 diabetes and the risk of Parkinson's disease. ( Buring, JE; Driver, JA; Gaziano, JM; Kurth, T; Logroscino, G; Smith, A, 2008)
"Aspirin was not associated with significant mortality benefit in diabetes sufferers (95% CI 0."	1.35	Aspirin and mortality in patients with diabetes sustaining acute coronary syndrome. ( Abbas, A; Barth, JH; Cubbon, RM; Das, R; Gale, CP; Grant, PJ; Hall, AS; Kearney, MT; Morrell, C; Rajwani, A, 2008)
"Treatment with aspirin and statin for every patient with diabetes has been postulated."	1.35	Should we be more aggressive in the therapy against cardiovascular risk factors? Should we prescribe statin and aspirin for every diabetic patient, or is it time for a polypill? ( Stirban, AO; Tschoepe, D, 2008)
"Patients with type 2 diabetes from July 2004 to June 2005 were included."	1.35	Control of cardiovascular risk factors and use of aspirin in diabetic patients remain elusive. ( Garg, P; Jeevanantham, V; Khan, A; Nautiyal, A; Reddy, PC; Shrivastava, R, 2008)
"Aspirin (30 mg/kg) treatment also reduced platelet aggregation."	1.35	Aspirin attenuates cerebral ischemic injury in diabetic rats. ( Fu, FH; Han, B; Wang, T; Yu, X; Zhang, LM; Zhu, M, 2009)
"Aspirin responders were defined when closure time was > or =300 s."	1.33	Prevalence of aspirin resistance in patients with type 2 diabetes. ( Bocksch, W; Cabeza, N; Dietz, R; Ersel, S; Fateh-Moghadam, S; Gawaz, M; Htun, P; Plöckinger, U; Reuter, T, 2005)
"Dyslipidemia is associated with macular exudates and vision loss."	1.32	Preventing diabetic retinopathy through control of systemic factors. ( Fong, D; Jain, A; Sarraf, D, 2003)
"Aspirin was used regularly by 37% of those with CVD and by 13% of those with risk factors only Adjusted odds of regular aspirin use were significantly greater for individuals with CVD than for those with one CVD risk factor (odds ratio [OR] = 4."	1.31	Aspirin use among adults with diabetes: estimates from the Third National Health and Nutrition Examination Survey. ( Fagot-Campagna, A; Narayan, KM; Rolka, DB, 2001)
"Aspirin was used by 85/291 (29%) male versus 56/259 (22%) females (p 0."	1.31	Low aspirin use in diabetics. ( Ahmed, MM; Akbar, DH; Siddique, AM, 2002)
"Muscle infarction is a rare complication in patients with diabetes mellitus, probably because of the rich vascular supply of this tissue."	1.30	Enhanced platelet aggregation, high homocysteine level, and microvascular disease in diabetic muscle infarctions: implications for therapy. ( Levy, J; Ragatzki, P; Rajkumar, V; Sima, A, 1999)

Research

Studies (210)

Authors

Clinical Trials (19)

Trial Overview

Trial Outcomes

5-year Composite Endpoint of All-cause Mortality, Non-fatal Myocardial Infarction, and Stroke

All-cause Mortality

Major MACCE Rates, Including the First of One of the Following: Death, Myocardial Infarction, Stroke, or Repeat Revascularization

Rates of Individual MACCE Endpoints

Timeframe	Studies, this research(%)	All Research%
pre-1990	19 (9.05)	18.7374
1990's	24 (11.43)	18.2507
2000's	103 (49.05)	29.6817
2010's	60 (28.57)	24.3611
2020's	4 (1.90)	2.80

Authors	Studies
Ma, H	1
Gu, Q	1
Niu, H	1
Li, X	1
Wang, R	1
Su, YJ	1
Leong, PY	1
Wang, YH	1
Wei, JC	1
Clemens, KK	1
Woodward, M	1
Neal, B	1
Zinman, B	1
Schlögl, M	1
Hofmänner, D	1
Manka, R	1
Keller, DI	1
Chamberlain, JJ	1
Johnson, EL	1
Leal, S	1
Rhinehart, AS	1
Shubrook, JH	1
Peterson, L	1
Foster, JG	1
Wood, SK	1
Pfeffer, MA	1
DeMets, DL	1
Garber, A	1
Hennekens, CH	1
Bonaventura, A	1
Liberale, L	1
Montecucco, F	1
Rosenson, RS	2
Chen, Q	1
Najera, SD	1
Lee, ML	1
Cho, DJ	1
Ajjan, RA	2
Khan, SU	1
Ul Abideen Asad, Z	1
Khan, MU	1
Talluri, S	1
Ali, F	1
Shahzeb Khan, M	1
Lone, AN	1
Mookadam, F	1
Krasuski, RA	1
Kaluski, E	2
Tsujimoto, T	1
Kajio, H	1
Raber, I	1
McCarthy, CP	1
Vaduganathan, M	1
Bhatt, DL	3
Wood, DA	1
Cleland, JGF	1
Blumenthal, RS	1
McEvoy, JW	1
Capranzano, P	4
Capodanno, D	4
Fatima, N	1
Pingali, U	1
Muralidhar, N	1
Raghavan, RP	1
Laight, DW	1
Cummings, MH	1
Alexopoulos, D	1
Joseph, JJ	1
Golden, SH	1
Neergaard-Petersen, S	1
Hvas, AM	1
Kristensen, SD	1
Grove, EL	2
Larsen, SB	1
Phoenix, F	1
Kurdee, Z	1
Grant, PJ	3
Desai, D	1
Ahmed, HM	1
Michos, ED	1
Bethel, MA	1
Harrison, P	1
Sourij, H	1
Sun, Y	1
Tucker, L	1
Kennedy, I	1
White, S	1
Hill, L	1
Oulhaj, A	1
Coleman, RL	1
Holman, RR	2
Kunutsor, SK	1
Seidu, S	1
Khunti, K	1
Ngalesoni, FN	1
Ruhago, GM	1
Mori, AT	1
Robberstad, B	1
Norheim, OF	1
Faucon, AL	1
Madjalian, AM	1
Bobrie, G	1
Amar, L	1
Azizi, M	1
van Diepen, S	1
Fuster, V	1
Verma, S	1
Hamza, TH	1
Siami, FS	1
Goodman, SG	1
Farkouh, ME	2
Thott, O	1
Granath, F	1
Malmstedt, J	1
Wahlgren, CM	1
Angiolillo, DJ	9
Goto, S	1
Aslam, M	1
Desai, B	3
Charlton, RK	1
Suzuki, Y	1
Box, LC	1
Shoemaker, SB	1
Zenni, MM	1
Guzman, LA	1
Bass, TA	4
Driver, JA	1
Smith, A	1
Buring, JE	1
Gaziano, JM	1
Kurth, T	1
Logroscino, G	1
Kahn, R	1
Robertson, RM	1
Smith, R	1
Eddy, D	1
Engberding, N	1
Wenger, NK	1
Belch, J	1
MacCuish, A	1
Campbell, I	1
Cobbe, S	1
Taylor, R	1
Prescott, R	1
Lee, R	1
Bancroft, J	1
MacEwan, S	1
Shepherd, J	1
Macfarlane, P	1
Morris, A	1
Jung, R	1
Kelly, C	1
Connacher, A	1
Peden, N	1
Jamieson, A	1
Matthews, D	1
Leese, G	1
McKnight, J	1
O'Brien, I	1
Semple, C	1
Petrie, J	1
Gordon, D	1
Pringle, S	1
MacWalter, R	1
Walsh, M	1
Spurling, G	1
Nicolucci, A	4
Ogawa, H	5
Nakayama, M	4
Morimoto, T	4
Uemura, S	4
Kanauchi, M	3
Doi, N	4
Jinnouchi, H	4
Sugiyama, S	3
Saito, Y	4
Federman, DG	1
Shelling, M	1
Prodanovich, S	1
Gunderson, CG	1
Kirsner, RS	1
Cleland, JG	1
Elwood, P	1
Cerbone, AM	2
Macarone-Palmieri, N	1
Saldalamacchia, G	1
Coppola, A	1
Di Minno, G	4
Rivellese, AA	1
Wang, T	1
Fu, FH	1
Han, B	1
Zhu, M	1
Yu, X	1
Zhang, LM	1
Zaslavskaia, RM	1
Tulemisov, EU	1
Manrique, C	1
Lastra, G	1
Palmer, J	1
Gardner, M	1
Sowers, JR	1
Price, HC	1
Azuz, N	1
Thomas, K	1
Yaffe, Y	1
Katz, M	1
Weingarten, M	1
Matalon, A	1
Merkely, B	1
Tóth-Zsamboki, E	1
Becker, D	1
Beres, BJ	1
Szabó, G	1
Vargova, K	1
Fülöp, G	1
Kerecsen, G	1
Preda, I	1
Spaulding, C	1
Kiss, RG	1
Pulcinelli, FM	1
Biasucci, LM	1
Riondino, S	1
Giubilato, S	1
Leo, A	1
Di Renzo, L	1
Trifirò, E	1
Mattiello, T	1
Pitocco, D	1
Liuzzo, G	1
Ghirlanda, G	1
Crea, F	1
Singla, MK	1
Lahiri, P	1
Mukhopadhyay, P	1
Pandit, K	1
Chaudhuri, U	1
Chowdhury, S	1
Jackson, G	1
Younis, N	1
Williams, S	1
Soran, H	1
Calvin, AD	1
Aggarwal, NR	1
Murad, MH	1
Shi, Q	1
Elamin, MB	1
Geske, JB	1
Fernandez-Balsells, MM	1
Albuquerque, FN	1
Lampropulos, JF	1
Erwin, PJ	1
Smith, SA	1
Montori, VM	1
Davis, TM	2
Sillars, BA	1
Davis, WA	2
Singla, A	2
Antonino, MJ	2
Bliden, KP	3
Tantry, US	3
Gurbel, PA	3
Zhang, C	1
Sun, A	1
Zhang, P	1
Wu, C	1
Zhang, S	1
Fu, M	1
Wang, K	1
Zou, Y	1
Ge, J	1
Philipp, S	1
Böse, D	1
Wijns, W	1
Marso, SP	2
Schwartz, RS	1
König, A	1
Lerman, A	1
Garcia-Garcia, HM	1
Serruys, PW	1
Erbel, R	1
Araki, S	1
Kashiwagi, A	1
De Berardis, G	2
Sacco, M	3
Strippoli, GF	1
Pellegrini, F	2
Graziano, G	1
Tognoni, G	3
Haynes, R	1
Bowman, L	1
Armitage, J	1
Ong, G	1
Song, SH	2
Gray, TA	1
Tesfaye, S	1
Bernardo, E	2
Vivas, D	1
Sabaté, M	3
Ferreiro, JL	4
Ueno, M	3
Jimenez-Quevedo, P	3
Alfonso, F	3
Macaya, C	3
Fernandez-Ortiz, A	2
Asghari, S	1
Courteau, J	1
Drouin, C	1
Grégoire, JP	1
Carpentier, AC	1
Pâquet, M	1
Vanasse, A	1
Soejima, H	4
Davì, G	2
Santilli, F	1
Mannucci, PM	1
Pignone, M	1
Alberts, MJ	1
Colwell, JA	16
Cushman, M	1
Inzucchi, SE	1
Mukherjee, D	1
Williams, CD	1
Wilson, PW	1
Kirkman, MS	1
Yassine, HN	1
Davis-Gorman, G	1
Stump, CS	1
Thomson, SS	1
Peterson, J	1
McDonagh, PF	1
Addad, F	1
Chakroun, T	1
Elalamy, I	1
Abderazek, F	1
Chouchene, S	1
Dridi, Z	1
Gerotziafas, GT	1
Hatmi, M	1
Hassine, M	1
Gamra, H	1
Wang, J	2
Zhu, YQ	2
Liu, F	2
Li, MH	2
Zhao, JG	2
Tan, HQ	2
Wang, JB	2
Cheng, YS	2
Zhang, PL	1
Rhee, SY	2
Kim, YS	2
Chon, S	1
Oh, S	2
Woo, JT	1
Kim, SW	1
Kim, JW	1
Sanchez-Ross, M	1
Waller, AH	1
Maher, J	1
Klapholz, M	1
Haider, B	1
Kautzky-Willer, A	1
Kamyar, MR	1
Gerhat, D	1
Handisurya, A	1
Stemer, G	1
Hudson, S	1
Luger, A	1
Lemmens-Gruber, R	1
Badimon, JJ	1
Saucedo, JF	1
Frelinger, AL	1
Michelson, AD	1
Jakubowski, JA	1
Zhu, B	1
Ojeh, CK	1
Baker, BA	1
Effron, MB	1
Waki, M	3
Okada, S	3
Akai, Y	1
Liu, D	1
Tang, JY	1
Yan, L	1
Yawn, BP	1
Chase, J	1
Averbeck, B	1
Walling, L	1
Lim, K	1
Patel, A	1
Dharmashankar, K	2
Kodali, M	1
Tomasello, SD	1
Seecheran, N	1
Darlington, A	2
Tello-Montoliu, A	3
DiChiara, J	2
Sakuma, M	2
Spectre, G	1
Arnetz, L	1
Östenson, CG	1
Brismar, K	1
Li, N	1
Hjemdahl, P	1
Nandish, S	1
Wyatt, J	1
Bailon, O	2
Smith, M	1
Oliveros, R	1
Chilton, R	1
Santos, MT	1
Moscardo, A	1
Vallés, J	1
Di Minno, MN	1
Lupoli, R	1
Palmieri, NM	1
Russolillo, A	1
Buonauro, A	1
Gregersen, S	1
Rollini, F	1
Manzano-Fernández, S	1
Marín, F	1
Park, SY	1
Kwon, HS	1
Cha, BY	1
Lee, HJ	1
Lee, HC	1
Al-Azzam, SI	1
Alzoubi, KH	1
Khabour, O	1
Alowidi, A	1
Tawalbeh, D	1
Dillinger, JG	1
Drissa, A	1
Sideris, G	1
Bal dit Sollier, C	1
Voicu, S	1
Manzo Silberman, S	1
Logeart, D	1
Drouet, L	1
Henry, P	1
de Boer, HC	1
van Solingen, C	1
Prins, J	1
Duijs, JM	1
Huisman, MV	2
Rabelink, TJ	1
van Zonneveld, AJ	1
Cavarretta, E	1
Chiariello, GA	1
Condorelli, G	1
Hirsch, AT	1
Ringleb, PA	1
Hacke, W	1
Topol, EJ	2
Ersöz, G	1
Tikiz, H	1
Yakaryilmaz, A	1
Tezcan, K	1
Genç, Y	1
Korkmaz, S	1
Jönsson, B	1
Hansson, L	1
Stålhammar, NO	1
Ali Raza, J	1
Movahed, A	1
Nesto, RW	1
Vaur, L	1
Danchin, N	1
Hanania, G	1
Cambou, JP	1
Lablanche, JM	1
Blanchard, D	1
Clerson, P	1
Gueret, P	1
McCall, AL	1
Jain, A	1
Sarraf, D	1
Fong, D	1
Roncaglioni, MC	1
Avanzini, F	1
Gitt, AK	2
Schiele, R	1
Wienbergen, H	2
Zeymer, U	1
Schneider, S	1
Gottwik, MG	1
Senges, J	2
Esmatjes, E	1
Castell, C	1
Franch, J	1
Puigoriol, E	1
Hernáez, R	1
Bueno, H	1
Brown, PM	1
Zácková, V	1
Gale, E	1
Violi, F	2
Gresele, P	1

Trial	Phase	Enrollment	Study Type	Start Date	Status
The Impact of Meal Timing on Neurovascular Control in Adults[NCT04133701]		34 participants (Actual)	Interventional	2022-02-02	Completed
The Links Between Dysglycaemia, Insulin Resistance, Endothelial Function, Inflammation and Oxidative Stress: Effect of Different Doses of Aspirin in Subjects With Type-2 Diabetes and High Cardiovascular Risk[NCT00898950]		21 participants (Actual)	Interventional	2004-08-31	Completed
Future Revascularization Evaluation in Patients With Diabetes Mellitus: Optimal Management of Multivessel Disease (FREEDOM)[NCT00086450]	Phase 3	1,900 participants (Actual)	Interventional	2004-04-30	Active, not recruiting
Comparison of Platelet Inhibitory Effect With Adjunctive Cilostazol Versus High Maintenance-dose ClopidogrEL in Acute Myocardial Infarction Patients According to CYP2C19 Polymorphism[NCT00915733]	Phase 4	80 participants (Actual)	Interventional	2009-05-31	Completed
The Impact of Aspirin Dose Modification on the Innate Immune Response - Will Lower Dose Aspirin Therapy Reduce the Response to Endotoxin[NCT03869268]	Phase 4	72 participants (Actual)	Interventional	2019-04-24	Completed
Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial[NCT00110448]	Phase 4	2,539 participants (Actual)	Interventional	2002-12-31	Completed
Effect of aSpirin Versus CilOstazol for Inhibition of Antiplatelet aggRegaTion in Type 2 DM Patients[NCT02933788]	Phase 4	116 participants (Anticipated)	Interventional	2016-10-31	Not yet recruiting
The Role of Multiple Electrode Aggregometry in Detection of Clopidogrel Resistance in Diabetic Patients With Coronary Artery Disease and Prediction of Clinical Outcomes. A Comparative-method, Non Interventional, Single Center Study.[NCT01991093]		280 participants (Actual)	Observational	2014-06-30	Completed
DPP-4 Inhibitors in Patients With Type 2 Diabetes and Acute Myocardial Infarction:Effects on Platelet Function[NCT02377388]	Phase 3	74 participants (Actual)	Interventional	2017-02-07	Completed
Platelet Reactivity in Patients With Chronic Kidney Disease Receiving Adjunctive Cilostazol Compared to a High-maintenance Dose of Clopidogrel[NCT01328470]	Phase 4	85 participants (Actual)	Interventional	2009-09-30	Completed
A Pharmacodynamic Comparison of Prasugrel (LY640315) Versus High Dose Clopidogrel in Subjects With Type 2 Diabetes Mellitus and Coronary Artery Disease.[NCT00642174]	Phase 2	35 participants (Actual)	Interventional	2008-04-30	Completed
Pharmacodynamic Effects of Different Aspirin Dosing Regimens in Type 2 Diabetes Mellitus Patients With Coronary Artery Disease[NCT01201785]	Phase 4	20 participants (Actual)	Interventional	2009-01-31	Completed
Comparison of Triflusal With Aspirin in the Secondary Prevention of Atherothrombotic Events[NCT02616497]	Phase 4	1,220 participants (Actual)	Interventional	2015-09-30	Completed
Impact on the Oxidative Stress of the Different Analogues of Insulin in People With Type 1 Diabetes. Clinical Trial of Low Level of Intervention. (Ineox Study)[NCT03328845]	Phase 4	300 participants (Actual)	Interventional	2017-01-20	Completed
A Randomized, Open-label, Active-controlled, Parallel-group Study to Investigate the Platelet Inhibition of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease and Type 2 Diabetes Mellitus After Recent Elective Percutaneous Coron[NCT02748330]	Phase 4	40 participants (Actual)	Interventional	2016-06-30	Completed
Effects of Pulsatile IV Insulin Delivery on Diabetic Retinopathy[NCT00287651]	Phase 2/Phase 3	150 participants (Actual)	Interventional	2005-11-30	Terminated (stopped due to Administrative)
Prevalence of Aspirin Resistance in Ischemic Stroke Patients at Assiut University Hospital[NCT05151263]		133 participants (Anticipated)	Observational	2023-11-01	Not yet recruiting
Acetylsalicylic Acid Administered in Patients With Type 2 Diabetes Mellitus and Its Effect on the Antioxidant Enzyme System[NCT03341117]	Phase 3	21 participants (Actual)	Interventional	2014-12-02	Completed
Effects of Low and High Doses of Aspirin Treatment on Fibrin Network Formation in Patients With Type 1 Diabetes and Possible Influence of the Glycemic Control.[NCT01397513]	Phase 4	48 participants (Actual)	Interventional	2006-03-31	Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Intervention	percentage of participants (Number)
Percutaneous Coronary Intervention	26.6
Coronary Artery Bypass Graft	18.7

Intervention	percentage of participants (Number)
Percutaneous Coronary Intervention	16.3
Coronary Artery Bypass Graft	10.9

Intervention	percentage of participants (Number)
Percutaneous Coronary Intervention	16.8
Coronary Artery Bypass Graft	11.8

Major adverse cardiovascular and cerebrovascular events (NCT00086450)
Timeframe: Measured at Day 30

Inhibition of Platelet Aggregation (IPA) 4 Hours After Loading Dose Assessed by Accumetrics VerifyNow™ P2Y12 Assay

Intervention	percentage of participants (Number)
Percutaneous Coronary Intervention	4.8
Coronary Artery Bypass Graft	5.2

The inhibition of platelet aggregation 4 hours after the loading dose was administered was assessed using the Accumetrics VerifyNow™ P2Y12 assay. Percentage inhibition, as reported by VerifyNow™ P2Y12, was calculated from P2Y12 Reaction Unit (PRU) (rate and extent of adenosine diphosphate [ADP]-stimulated platelet aggregation) and BASE (estimate of baseline platelet reactivity independent of P2Y12 receptor inhibition [reference values]: rate and extent of Thrombin Receptor-Activated Peptide-stimulated platelet aggregation) values as follows: Percentage (%) inhibition = (1-PRU/BASE) x 100. (NCT00642174)
Timeframe: 4 hours after loading dose

Inhibition of Platelet Aggregation at 1- and 24-Hours After Loading Dose (LD) and 24-Hours After Last Maintenance Dose (LMD) Assessed by Accumetrics VerifyNow™ P2Y12 Assay

Intervention	percent inhibition (Least Squares Mean)
	Baseline	4 Hours After Loading Dose
Clopidogrel	9.3	27.7
Prasugrel	9.4	89.3

Inhibition of platelet aggregation 1- and 24-hours after loading dose and 24-hours after last maintenance dose was administered was assessed using Accumetrics VerifyNow™ P2Y12 assay. Percentage inhibition, as reported by VerifyNow™ P2Y12, was calculated from PRU (rate and extent of ADP-stimulated platelet aggregation) and BASE (estimate of baseline platelet reactivity independent of P2Y12 receptor inhibition [reference values]: rate and extent of Thrombin Receptor-Activated Peptide-stimulated platelet aggregation) values as follows: Percentage (%) inhibition = (1-PRU/BASE) x 100. (NCT00642174)
Timeframe: 1 hour and 24 hours after the loading dose (LD) and 24 hours after the last maintenance dose (LMD)

Inhibition of Platelet Function as Measured by Thromboelastography (TEG)-Platelet Mapping Maximum Amplitude - Adenosine Diphosphate

Intervention	percent inhibition (Least Squares Mean)
	1 Hour After Loading Dose	24 Hours After Loading Dose	24 Hours After Last Maintenance Dose
Clopidogrel	13.4	29.3	44.2
Prasugrel	49.9	87.1	61.8

Thromboelastography (TEG) platelet mapping (MP) maximum amplitude (MA) - Adenosine Diphosphate (ADP) millimeters (mm) at each time point. The TEG-MP MA measures strength of clot formation in whole blood. MA-ADP is the maximal amplitude resulting from fibrin and platelets not blocked by ADP-receptor inhibiting drugs. Fibrin strands in blood sample link a rotating sample cup with a stationary pin suspended by a torsion wire. The degree of platelet contribution to the MA through platelet-fibrin bonding directly influences the magnitude of pin movement and ultimately the amplitude of the tracing. (NCT00642174)
Timeframe: Baseline, 1 Hour, 4 Hours, and 24 Hours after loading dose, and 24 Hours after last maintenance dose

Maximum Platelet Aggregation (MPA) as Assessed by Light Transmittance Aggregometry (LTA)

Intervention	millimeters (mm) (Least Squares Mean)
	Baseline	1 Hour After Loading Dose	4 Hours After Loading Dose	24 Hours After Loading Dose	24 Hours After Last Maintenance Dose
Clopidogrel	58.1	54.8	48.1	49.2	46.8
Prasugrel	56.8	38.5	24.2	29.3	44.2

Mean platelet aggregation (MPA) to 5 and 20 µM adenosine diphosphate (ADP) was assessed by light transmittance aggregometry (LTA). Platelet aggregation was monitored for a total of 7 minutes after addition of ADP. Maximum platelet aggregation was the maximal aggregation value achieved during the 7-minute observation period following addition of agonists. (NCT00642174)
Timeframe: Baseline, 1 Hour, 4 Hours, and 24 Hours after loading dose, and 24 Hours after last maintenance dose

Platelet Reactivity Index (PRI)

Intervention	percent platelet aggregation (Least Squares Mean)
	Baseline (5 μM ADP)	1 Hour After Loading Dose (5 μM ADP)	4 Hours After Loading Dose (5 μM ADP)	24 Hours After Loading Dose (5 μM ADP)	24 Hours After Last Maintenance Dose (5 μM ADP)	Baseline (20 μM ADP)	1 Hour After Loading Dose (20 μM ADP)	4 Hours After Loading Dose (20 μM ADP)	24 Hours After Loading Dose (20 μM ADP)	24 Hours After Last Maintenance Dose (20 μM ADP)
Clopidogrel	65.7	56.7	44.6	45.6	38.3	76.9	69.8	57.5	58.4	50.7
Prasugrel	64.9	33.7	18.0	22.3	29.6	77.1	44.7	22.4	27.4	38.3

Data from the Vasodilator-associated stimulated phosphoprotein assay were reported as the platelet reactivity index (PRI) which was calculated from corrected mean fluorescence intensity (cMFI) following incubation of platelets with either prostaglandin E1 (PGE1) alone or PGE1 plus ADP: Platelet Reactivity Index (%) = [1-(cMFI PGEI+ADP/cMFI PGEI)] x 100. Lower PRI values indicate greater platelet P2Y12 inhibition. (NCT00642174)
Timeframe: Baseline, 1 Hour, 4 Hours, and 24 Hours after loading dose, and 24 Hours after last maintenance dose

Collagen Induced Aggregation

Intervention	percent inhibition (Least Squares Mean)
	Baseline	1 Hour After Loading Dose	4 Hours After Loading Dose	24 Hours After Loading Dose	24 Hours After Last Maintenance Dose
Clopidogrel	80.6	76.2	67.5	58.5	42.3
Prasugrel	83.5	40.0	14.5	15.7	27.4

Collagen induced aggregation using light transmittance aggregometry (NCT01201785)
Timeframe: after 1 -week of treatment

Article	Year
Benefits and Risks Associated With Aspirin Use in Patients With Diabetes for the Primary Prevention of Cardiovascular Events and Mortality: A Meta-Analysis. Frontiers in endocrinology, 2021, Volume: 12 Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetic Angiopathies; Diabetic Cardiomyop	2021
Sex Disparities in Cardiovascular Outcome Trials of Populations With Diabetes: A Systematic Review and Meta-analysis. Diabetes care, 2020, Volume: 43, Issue:5 Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Dis	2020
Aspirin in primary prevention for patients with diabetes: Still a matter of debate. European journal of clinical investigation, 2018, Volume: 48, Issue:10 Topics: Aspirin; Blood Platelets; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathie	2018
Aspirin for primary prevention of cardiovascular outcomes in diabetes mellitus: An updated systematic review and meta-analysis. European journal of preventive cardiology, 2020, Volume: 27, Issue:19 Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Diabetic Angiopathies; Humans; Platelet Aggrega	2020
The rise and fall of aspirin in the primary prevention of cardiovascular disease. Lancet (London, England), 2019, 05-25, Volume: 393, Issue:10186 Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Cyclooxy	2019
Dual antiplatelet therapy in patients with diabetes mellitus: special considerations. Expert review of cardiovascular therapy, 2013, Volume: 11, Issue:3 Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Diabetes Mellitus; Diabetic Angiopat	2013
p2y12 receptor inhibitors in acute coronary syndromes: from the research laboratory to the clinic and vice versa. Cardiology, 2014, Volume: 127, Issue:4 Topics: Acute Coronary Syndrome; Aspirin; Clinical Trials as Topic; Clopidogrel; Diabetic Angiopathies; Huma	2014
Type 2 diabetes and cardiovascular disease: what next? Current opinion in endocrinology, diabetes, and obesity, 2014, Volume: 21, Issue:2 Topics: Anticholesteremic Agents; Aspirin; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus, Type 2	2014
Preventing cardiovascular disease in patients with diabetes: use of aspirin for primary prevention. Current cardiology reports, 2015, Volume: 17, Issue:3 Topics: Aspirin; Cardiovascular Diseases; Diabetic Angiopathies; Evidence-Based Medicine; Humans; Patient Se	2015
Aspirin for primary prevention of cardiovascular and all-cause mortality events in diabetes: updated meta-analysis of randomized controlled trials. Diabetic medicine : a journal of the British Diabetic Association, 2017, Volume: 34, Issue:3 Topics: Aspirin; Cardiovascular Diseases; Diabetic Angiopathies; Diabetic Cardiomyopathies; Evidence-Based M	2017
The impact of prevention on reducing the burden of cardiovascular disease. Diabetes care, 2008, Volume: 31, Issue:8 Topics: Adult; Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Cost of Illness; Costs and Cost A	2008
Cardiovascular disease prevention tailored for women. Expert review of cardiovascular therapy, 2008, Volume: 6, Issue:8 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Body Mass Index; Cardiovascular Diseases; Choleste	2008
Psoriasis: an opportunity to identify cardiovascular risk. The British journal of dermatology, 2009, Volume: 160, Issue:1 Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dyslipidemias; F	2009
Diabetes, vascular complications and antiplatelet therapy: open problems. Acta diabetologica, 2009, Volume: 46, Issue:4 Topics: Aspirin; Clopidogrel; Diabetes Mellitus; Diabetic Angiopathies; Drug Interactions; Drug Resistance;	2009
Aspirin and Diabetes Mellitus: revisiting an old player. Therapeutic advances in cardiovascular disease, 2008, Volume: 2, Issue:1 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus, Type 2; Diabetic Angiopathies;	2008
Antiplatelet therapy in diabetes: efficacy and limitations of current treatment strategies and future directions. Diabetes care, 2009, Volume: 32, Issue:4 Topics: Aspirin; Clopidogrel; Diabetes Mellitus; Diabetic Angiopathies; Drug Resistance; Humans; Platelet Ac	2009
Aspirin therapy and primary prevention of cardiovascular disease in diabetes mellitus. Diabetes, obesity & metabolism, 2009, Volume: 11, Issue:11 Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Diabetic Angiopathies; Female; Fibrinolytic Age	2009
Aspirin for the primary prevention of cardiovascular events: a systematic review and meta-analysis comparing patients with and without diabetes. Diabetes care, 2009, Volume: 32, Issue:12 Topics: Aspirin; Cardiovascular Diseases; Diabetic Angiopathies; Female; Fibrinolytic Agents; Humans; Hypert	2009
Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis. Diabetes research and clinical practice, 2010, Volume: 87, Issue:2 Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans;	2010
Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ (Clinical research ed.), 2009, Nov-06, Volume: 339 Topics: Aspirin; Cardiovascular Agents; Diabetic Angiopathies; Female; Humans; Male; Primary Prevention; Pro	2009
Aspirin for primary prevention of cardiovascular events in people with diabetes. Journal of the American College of Cardiology, 2010, Jun-22, Volume: 55, Issue:25 Topics: Aged; Aspirin; Cardiovascular Diseases; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiop	2010
Aspirin for the prevention of cardiovascular morbidity. Minerva medica, 2010, Volume: 101, Issue:4 Topics: Aspirin; Cardiovascular Diseases; Diabetic Angiopathies; Female; Humans; Male; Myocardial Infarction	2010
Implementing cardiovascular risk reduction in patients with cardiovascular disease and diabetes mellitus. The American journal of cardiology, 2011, Aug-02, Volume: 108, Issue:3 Suppl Topics: Aspirin; Atherosclerosis; Biomarkers; Calcium; Coronary Vessels; Diabetic Angiopathies; Disease Prog	2011
Aspirin resistance, platelet turnover, and diabetic angiopathy: a 2011 update. Thrombosis research, 2012, Volume: 129, Issue:3 Topics: Animals; Aspirin; Blood Platelets; Diabetic Angiopathies; Drug Resistance; Humans; Platelet Aggregat	2012
Antiplatelet therapy in patients with diabetes mellitus. Current vascular pharmacology, 2012, Volume: 10, Issue:4 Topics: Animals; Aspirin; Blood Platelets; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic An	2012
Challenges and perspectives of antiplatelet therapy in patients with diabetes mellitus and coronary artery disease. Current pharmaceutical design, 2012, Volume: 18, Issue:33 Topics: Aspirin; Blood Glucose; Blood Platelets; Clopidogrel; Coronary Artery Disease; Diabetes Mellitus, Ty	2012
Current concepts of cardiovascular diseases in diabetes mellitus. International journal of cardiology, 2003, Volume: 89, Issue:2-3 Topics: Aspirin; Cardiovascular Diseases; Coronary Artery Disease; Diabetes Complications; Diabetes Mellitus	2003
The platelet in diabetes: focus on prevention of ischemic events. Diabetes care, 2003, Volume: 26, Issue:7 Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Diabetes Mellitus; Diabetic Angiopathies; Humans;	2003
The Polypill and type 2 diabetes. Diabetic medicine : a journal of the British Diabetic Association, 2004, Volume: 21 Suppl 1 Topics: Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents; Aspirin; Diabetes Mellitus, Type	2004
Prevention of cardiovascular events in diabetes. Clinical evidence, 2003, Issue:10 Topics: Angioplasty, Balloon; Antihypertensive Agents; Aspirin; Cardiovascular Diseases; Clopidogrel; Corona	2003
Prevention of cardiovascular events in diabetes. Clinical evidence, 2004, Issue:11 Topics: Angioplasty, Balloon; Antihypertensive Agents; Aspirin; Bezafibrate; Cardiovascular Diseases; Corona	2004
Aspirin response and failure in diabetic patients with cardiovascular disease. Current opinion in pharmacology, 2005, Volume: 5, Issue:2 Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans	2005
Keeping the diabetic heart healthy. Australian family physician, 2005, Volume: 34, Issue:6 Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Family Practice;	2005
Blood platelet abnormalities and pharmacological modulation of platelet reactivity in patients with diabetes mellitus. Pharmacological reports : PR, 2005, Volume: 57 Suppl Topics: Aspirin; Blood Platelets; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathie	2005
"Anti-inflammatory" drugs and their effects on type 2 diabetes. Diabetes technology & therapeutics, 2006, Volume: 8, Issue:1 Topics: Angiotensin-Converting Enzyme Inhibitors; Anti-Inflammatory Agents; Aspirin; Cardiotonic Agents; Dia	2006
Stroke prevention in diabetes and obesity. Expert review of cardiovascular therapy, 2006, Volume: 4, Issue:4 Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atrial Fibrillation; Blood Glucose; Cardiovascular	2006
Prevention of cardiovascular events in diabetes. Clinical evidence, 2006, Issue:15 Topics: Angioplasty, Balloon; Antihypertensive Agents; Aspirin; Bezafibrate; Cardiovascular Diseases; Clopid	2006
[Screening and management of coronary artery disease in diabetic patients]. La Tunisie medicale, 2006, Volume: 84, Issue:10 Topics: Adrenergic beta-Antagonists; Aged; Angioplasty, Balloon, Coronary; Angiotensin-Converting Enzyme Inh	2006
Pharmacological prevention of atherothrombotic events in patients with peripheral arterial disease. European journal of clinical investigation, 2007, Volume: 37, Issue:3 Topics: Antihypertensive Agents; Aspirin; Cardiovascular Agents; Diabetic Angiopathies; Humans; Hydroxymethy	2007
Antiplatelet therapy for primary prevention in diabetes. Diabetes & metabolism, 2006, Volume: 32 Spec No2 Topics: Aspirin; Clinical Trials as Topic; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Diab	2006
[Low-dose aspirin in patients with diabete melitus: risks and benefits regarding macro and microvascular complications]. Arquivos brasileiros de endocrinologia e metabologia, 2007, Volume: 51, Issue:3 Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Diabetes Mellitus; Diabetic Angiopathies	2007
Preventing macrovascular complications in type 2 diabetes mellitus: glucose control and beyond. The American journal of cardiology, 2007, Jun-04, Volume: 99, Issue:11A Topics: Angiotensin-Converting Enzyme Inhibitors; Aspirin; Blood Glucose; Clinical Trials as Topic; Diabetes	2007
Platelet function in diabetes mellitus. British journal of haematology, 1980, Volume: 44, Issue:4 Topics: Animals; Arteriosclerosis; Aspirin; Blood Platelets; Cyclooxygenase Inhibitors; Diabetes Mellitus; D	1980
Antiplatelet agents in the prevention of diabetic vascular complications. Diabetes/metabolism reviews, 1993, Volume: 9, Issue:3 Topics: Aspirin; Diabetes Mellitus; Diabetic Angiopathies; Diabetic Nephropathies; Diabetic Retinopathy; Hum	1993
Incidence, natural history, and risk factors in lacunar infarction. Advances in neurology, 1993, Volume: 62 Topics: Age Factors; Aged; Aspirin; Cardiovascular Diseases; Cerebral Infarction; Diabetic Angiopathies; Fem	1993
Diabetes mellitus and peripheral vascular disease: is aspirin effective in preventing vascular events? Diabetologia, 1996, Volume: 39, Issue:11 Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Diabetes Complications; Diabetic Angiop	1996
Multifactorial aspects of the treatment of the type II diabetic patient. Metabolism: clinical and experimental, 1997, Volume: 46, Issue:12 Suppl 1 Topics: Arteriosclerosis; Aspirin; Cardiovascular Diseases; Cardiovascular Physiological Phenomena; Diabetes	1997
[Platelet aggregation inhibitors in diabetes mellitus]. Acta medica Austriaca, 1999, Volume: 26, Issue:5 Topics: Aspirin; Diabetes Mellitus; Diabetic Angiopathies; Humans; Platelet Aggregation; Platelet Aggregatio	1999
[Platelet function inhibitors as a way of arterial thrombosis prevention in the diabetic]. Journees annuelles de diabetologie de l'Hotel-Dieu, 2001 Topics: Aspirin; Diabetes Complications; Diabetic Angiopathies; France; Humans; Platelet Aggregation Inhibit	2001
[Diabetes and ischemic cardiopathy]. Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology, 2001, Volume: 2, Issue:9 Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Coronary Disease; Diabetic Angiopathies; Hu	2001
Proposed metabolic dysfunctions in diabetic microthromboses and microangiopathy. Metabolism: clinical and experimental, 1979, Volume: 28, Issue:4 Suppl 1 Topics: Alprostadil; Aspirin; Blood Platelets; Calcimycin; Collagen; Cyclic AMP; Cyclic GMP; Diabetes Mellit	1979
Morning peak in the incidence of myocardial infarction: experience in the ISIS-2 trial. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. European heart journal, 1992, Volume: 13, Issue:5 Topics: Adult; Age Factors; Aged; Aspirin; Circadian Rhythm; Diabetes Mellitus, Type 2; Diabetic Angiopathie	1992
[Acetylsalicylic acid in the treatment of arterial thromboembolytic diseases. 2. Clinical documentation]. Ugeskrift for laeger, 1989, Jun-19, Volume: 151, Issue:25 Topics: Aspirin; Cardiac Surgical Procedures; Diabetic Angiopathies; Female; Glomerulonephritis, Membranopro	1989
[Necrobiosis lipoidica without diabetes mellitus (diagnostic and therapeutic possibilities)]. Orvosi hetilap, 1989, Oct-01, Volume: 130, Issue:40 Topics: Aspirin; Basement Membrane; Capillaries; Diabetic Angiopathies; Diagnosis, Differential; Dipyridamol	1989
Antiplatelet agents and diabetic vascular disease. Transactions of the American Clinical and Climatological Association, 1987, Volume: 98 Topics: Aspirin; Blood Platelets; Diabetic Angiopathies; Dipyridamole; Humans	1987

Article	Year
Ticagrelor and the Prevention of Microvascular Complications in Diabetes Patients with Lower Extremity Arterial Disease; Rationale and Design of the Hema-Kinesis Trial. Cardiovascular drugs and therapy, 2018, Volume: 32, Issue:5 Topics: Aspirin; Blood Flow Velocity; Blood Viscosity; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabet	2018
Study of pharmacodynamic interaction of Phyllanthus emblica extract with clopidogrel and ecosprin in patients with type II diabetes mellitus. Phytomedicine : international journal of phytotherapy and phytopharmacology, 2014, Apr-15, Volume: 21, Issue:5 Topics: Aged; Aspirin; Clopidogrel; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fe	2014
Aspirin in type 2 diabetes, a randomised controlled study: effect of different doses on inflammation, oxidative stress, insulin resistance and endothelial function. International journal of clinical practice, 2014, Volume: 68, Issue:2 Topics: Adult; Aged; Aspirin; Biomarkers; Blood Glucose; Blood Pressure; Diabetes Mellitus, Type 2; Diabetic	2014
Randomized controlled trial comparing impact on platelet reactivity of twice-daily with once-daily aspirin in people with Type 2 diabetes. Diabetic medicine : a journal of the British Diabetic Association, 2016, Volume: 33, Issue:2 Topics: Adult; Aspirin; Cardiovascular Diseases; Cross-Over Studies; Cyclooxygenase Inhibitors; Diabetes Mel	2016
A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. European heart journal, 2008, Volume: 29, Issue:18 Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cilostazol; Clopidogrel; Coronary Artery Disease; Cross-Ove	2008
The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ (Clinical research ed.), 2008, Oct-16, Volume: 337 Topics: Adult; Aged; Antioxidants; Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic A	2008
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA, 2008, Nov-12, Volume: 300, Issue:18 Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus	2008
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA, 2008, Nov-12, Volume: 300, Issue:18 Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus	2008
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA, 2008, Nov-12, Volume: 300, Issue:18 Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus	2008
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA, 2008, Nov-12, Volume: 300, Issue:18 Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus	2008
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA, 2008, Nov-12, Volume: 300, Issue:18 Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus	2008
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA, 2008, Nov-12, Volume: 300, Issue:18 Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus	2008
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA, 2008, Nov-12, Volume: 300, Issue:18 Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus	2008
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA, 2008, Nov-12, Volume: 300, Issue:18 Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus	2008
Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. JAMA, 2008, Nov-12, Volume: 300, Issue:18 Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Cardiovascular Diseases; Diabetes Mellitus	2008
[Correction of the disturbed coagulation circadian rhythm in patients with type 1 diabetes mellitus treated by aspirin chronotherapy]. Klinicheskaia meditsina, 2008, Volume: 86, Issue:10 Topics: Administration, Oral; Adolescent; Adult; Aspirin; Blood Coagulation; Circadian Rhythm; Diabetes Mell	2008
[Investigation of the effects of low dose aspirin therapy on primary and secondary prevention of cardiovascular disease]. Nihon rinsho. Japanese journal of clinical medicine, 2010, Volume: 68, Issue:5 Topics: Aspirin; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Platelet Aggregation Inhibitors;	2010
Antiplatelet effect of once- or twice-daily aspirin dosage in stable coronary artery disease patients with diabetes. International journal of hematology, 2010, Volume: 92, Issue:2 Topics: Adult; Aged; Aspirin; Blood Platelets; Chemoprevention; Coronary Artery Disease; Diabetes Mellitus;	2010
Batroxobin for prevention of restenosis in diabetic patients after infrapopliteal arterial angioplasty: a small randomized pilot trial. Annals of vascular surgery, 2010, Volume: 24, Issue:7 Topics: Aged; Amputation, Surgical; Angioplasty; Ankle Brachial Index; Arterial Occlusive Diseases; Aspirin;	2010
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. European heart journal, 2011, Volume: 32, Issue:7 Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Diabetes	2011
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. European heart journal, 2011, Volume: 32, Issue:7 Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Diabetes	2011
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. European heart journal, 2011, Volume: 32, Issue:7 Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Diabetes	2011
A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial. European heart journal, 2011, Volume: 32, Issue:7 Topics: Adolescent; Adult; Aged; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over Studies; Diabetes	2011
Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial. Diabetes care, 2011, Volume: 34, Issue:2 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Atherosclerosis; Creatinine; Diabetes Mellit	2011
[Effect of compound danshen dripping pill on arterial intima-media thickness in patients with newly diagnosed type 2 diabetes mellitus]. Zhongguo Zhong xi yi jie he za zhi Zhongguo Zhongxiyi jiehe zazhi = Chinese journal of integrated traditional and Western medicine, 2010, Volume: 30, Issue:12 Topics: Adult; Aged; Aspirin; Blood Glucose; Carotid Intima-Media Thickness; Cholesterol; Diabetes Mellitus,	2010
Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease. Circulation. Cardiovascular interventions, 2011, Apr-01, Volume: 4, Issue:2 Topics: Aged; Aspirin; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Respo	2011
Differential effect of low-dose aspirin for primary prevention of atherosclerotic events in diabetes management: a subanalysis of the JPAD trial. Diabetes care, 2011, Volume: 34, Issue:6 Topics: Adult; Aged; Aged, 80 and over; Aspirin; Atherosclerosis; Diabetes Mellitus, Type 2; Diabetic Angiop	2011
Batroxobin plus aspirin reduces restenosis after angioplasty for arterial occlusive disease in diabetic patients with lower-limb ischemia. Journal of vascular and interventional radiology : JVIR, 2011, Volume: 22, Issue:7 Topics: Aged; Analysis of Variance; Angioplasty; Arterial Occlusive Diseases; Aspirin; Batroxobin; China; Co	2011
Twice daily dosing of aspirin improves platelet inhibition in whole blood in patients with type 2 diabetes mellitus and micro- or macrovascular complications. Thrombosis and haemostasis, 2011, Volume: 106, Issue:3 Topics: Aspirin; Blood Platelets; Cells, Cultured; Clinical Protocols; Diabetes Mellitus, Type 2; Diabetic A	2011
Pharmacodynamic effects of adjunctive cilostazol therapy in patients with coronary artery disease on dual antiplatelet therapy: impact of high on-treatment platelet reactivity and diabetes mellitus status. Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions, 2013, Jan-01, Volume: 81, Issue:1 Topics: Aged; Aspirin; Blood Platelets; Cilostazol; Clopidogrel; Coronary Artery Disease; Cross-Over Studies	2013
Aspirin reduces cerebrovascular events in type 2 diabetic patients with poorly controlled blood pressure. Subanalysis from the JPAD trial. Circulation journal : official journal of the Japanese Circulation Society, 2012, Volume: 76, Issue:6 Topics: Aged; Aspirin; Blood Pressure; Cardiovascular Agents; Cerebrovascular Disorders; Chi-Square Distribu	2012
Evaluation of the effectiveness of sarpogrelate on the surrogate markers for macrovascular complications in patients with type 2 diabetes. Endocrine journal, 2012, Volume: 59, Issue:8 Topics: Adiponectin; Adult; Aged; Ankle Brachial Index; Aspirin; Biomarkers; C-Reactive Protein; Carotid Int	2012
Biological efficacy of twice daily aspirin in type 2 diabetic patients with coronary artery disease. American heart journal, 2012, Volume: 164, Issue:4 Topics: Analysis of Variance; Arachidonic Acid; Aspirin; Clopidogrel; Coronary Artery Disease; Cross-Over St	2012
Amplified benefit of clopidogrel versus aspirin in patients with diabetes mellitus. The American journal of cardiology, 2002, Sep-15, Volume: 90, Issue:6 Topics: Aged; Aspirin; Clopidogrel; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Endpoi	2002
Health economics in the Hypertension Optimal Treatment (HOT) study: costs and cost-effectiveness of intensive blood pressure lowering and low-dose aspirin in patients with hypertension. Journal of internal medicine, 2003, Volume: 253, Issue:4 Topics: Aged; Antihypertensive Agents; Aspirin; Blood Pressure; Calcium Channel Blockers; Cost-Benefit Analy	2003
Reducing CVD risk in type 2 DM. Current diabetes reports, 2003, Volume: 3, Issue:5 Topics: Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Agents;	2003
Primary prevention of cardiovascular events with low-dose aspirin and vitamin E in type 2 diabetic patients: results of the Primary Prevention Project (PPP) trial. Diabetes care, 2003, Volume: 26, Issue:12 Topics: Aged; Aspirin; Blood Pressure; Body Mass Index; Cardiovascular Diseases; Diabetes Mellitus, Type 2;	2003
Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the DAVID study. European heart journal, 2004, Volume: 25, Issue:20 Topics: Adult; Aged; Aspirin; Diabetic Angiopathies; Double-Blind Method; Female; Follow-Up Studies; Humans;	2004
Long-term clinical benefit of sirolimus-eluting stent implantation in diabetic patients with de novo coronary stenoses: long-term results of the DIABETES trial. European heart journal, 2007, Volume: 28, Issue:16 Topics: Aged; Aspirin; Blood Vessel Prosthesis; Clopidogrel; Coronary Restenosis; Coronary Stenosis; Death,	2007
The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study. Diabetes, 2007, Volume: 56, Issue:12 Topics: Aged; Aspirin; Blood Platelets; Coronary Disease; Cross-Over Studies; Diabetic Angiopathies; Double-	2007
Effects of aspirin on serum C-reactive protein and interleukin-6 levels in patients with type 2 diabetes without cardiovascular disease: a randomized placebo-controlled crossover trial. Diabetes, obesity & metabolism, 2008, Volume: 10, Issue:8 Topics: Aspirin; Atherosclerosis; C-Reactive Protein; Cross-Over Studies; Diabetes Mellitus, Type 2; Diabeti	2008
Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in diabetic patients: the PLavix Use for Treatment Of Diabetes (PLUTO-Diabetes) trial. American heart journal, 2008, Volume: 155, Issue:1 Topics: Adult; Analysis of Variance; Aspirin; Biomarkers; Blood Chemical Analysis; Clopidogrel; Diabetes Mel	2008
Drug-eluting stenting followed by cilostazol treatment reduces late restenosis in patients with diabetes mellitus the DECLARE-DIABETES Trial (A Randomized Comparison of Triple Antiplatelet Therapy with Dual Antiplatelet Therapy After Drug-Eluting Stent Im Journal of the American College of Cardiology, 2008, Mar-25, Volume: 51, Issue:12 Topics: Aged; Aspirin; Cilostazol; Clopidogrel; Coronary Angiography; Coronary Artery Disease; Coronary Rest	2008
V.A. Cooperative Study on antiplatelet agents in diabetic patients after amputation for gangrene: I. Design, methods, and baseline characteristics. Controlled clinical trials, 1984, Volume: 5, Issue:2 Topics: Amputation, Surgical; Aspirin; Clinical Trials as Topic; Diabetic Angiopathies; Dipyridamole; Epopro	1984
[5-year controlled therapy study on the prevention of diabetic angiopathy with the platelet-function inhibitor acetylsalicylic acid]. Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1982, Oct-01, Volume: 37, Issue:19 Topics: Adult; Arterial Occlusive Diseases; Aspirin; Brain Ischemia; Coronary Disease; Diabetic Angiopathies	1982
Intensive insulin therapy in type II diabetes: rationale and collaborative clinical trial results. Diabetes, 1996, Volume: 45 Suppl 3 Topics: Arteriosclerosis; Aspirin; Blood Glucose; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Res	1996
Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators. Circulation, 1998, May-19, Volume: 97, Issue:19 Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Aspirin; Atherectomy; Blood Coagu	1998
[Beneficial effect of aspirin in diabetic coronary disease: facts to prove it]. Presse medicale (Paris, France : 1983), 1999, Jun-26, Volume: 28, Issue:23 Topics: Aspirin; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Retrospective S	1999
Morning peak in the incidence of myocardial infarction: experience in the ISIS-2 trial. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. European heart journal, 1992, Volume: 13, Issue:5 Topics: Adult; Age Factors; Aged; Aspirin; Circadian Rhythm; Diabetes Mellitus, Type 2; Diabetic Angiopathie	1992
Secondary prevention of strokes: role of platelet antiaggregant drugs in diabetic and non-diabetic patients. Diabetic medicine : a journal of the British Diabetic Association, 1985, Volume: 2, Issue:2 Topics: Aspirin; Cerebrovascular Disorders; Clinical Trials as Topic; Diabetic Angiopathies; Dipyridamole; D	1985
V.A. Cooperative Study on antiplatelet agents in diabetic patients after amputation for gangrene: III. Definitions and review of design and baseline characteristics. Hormone and metabolic research. Supplement series, 1985, Volume: 15 Topics: Amputation, Surgical; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic;	1985

Article	Year
Sjögren syndrome is a hidden contributor of macrovascular and microvascular complications in patients with type 2 diabetes. International journal of rheumatic diseases, 2022, Volume: 25, Issue:10 Topics: Aspirin; Case-Control Studies; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Hydroxychlo	2022
A foreign older diabetic woman with an acute myocardial infarction: when cognitive biases in clinical decision-making become especially important. BMJ case reports, 2018, Feb-05, Volume: 2018 Topics: Aged, 80 and over; Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clinical Decision-Making	2018
Cardiovascular Disease and Risk Management: Review of the American Diabetes Association Standards of Medical Care in Diabetes 2018. Annals of internal medicine, 2018, 05-01, Volume: 168, Issue:9 Topics: Adult; Antihypertensive Agents; Aspirin; Blood Pressure Monitoring, Ambulatory; Coronary Disease; Di	2018
ASPIRIN FOR PRIMARY PREVENTION IN PATIENTS WITH TYPE 2 DIABETES. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2018, Oct-02, Volume: 24, Issue:10 Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Patient	2018
Primary vascular prevention: The end of the road for aspirin? Diabetes & vascular disease research, 2018, Volume: 15, Issue:6 Topics: Aspirin; Clinical Trials as Topic; Diabetes Mellitus; Diabetic Angiopathies; Evidence-Based Medicine	2018
No beneficial effects of aspirin on secondary cardiovascular prevention in patients with type 2 diabetes using non-steroidal anti-inflammatory drugs. Diabetes, obesity & metabolism, 2019, Volume: 21, Issue:8 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; Diabetes Mellitus,	2019
The influence of type 2 diabetes on fibrin clot properties in patients with coronary artery disease. Thrombosis and haemostasis, 2014, Volume: 112, Issue:6 Topics: Aged; Aspirin; Blood Coagulation Tests; C-Reactive Protein; Case-Control Studies; Complement C3; Cor	2014
Cost-effectiveness of medical primary prevention strategies to reduce absolute risk of cardiovascular disease in Tanzania: a Markov modelling study. BMC health services research, 2016, 05-17, Volume: 16 Topics: Adult; Aged; Aged, 80 and over; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Calcium Channel B	2016
[Towards new targets in the treatment of hypertension?] Medecine sciences : M/S, 2016, Volume: 32, Issue:10 Topics: Aged; Angiotensin II Type 2 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihyperte	2016
Dual Antiplatelet Therapy Versus Aspirin Monotherapy in Diabetics With Multivessel Disease Undergoing CABG: FREEDOM Insights. Journal of the American College of Cardiology, 2017, Jan-17, Volume: 69, Issue:2 Topics: Acute Coronary Syndrome; Aged; Aspirin; Cause of Death; Clopidogrel; Diabetic Angiopathies; Drug The	2017
Editor's Choice - Dual Antiplatelet Therapy Improves Outcome in Diabetic Patients Undergoing Endovascular Femoropopliteal Stenting for Critical Limb Ischaemia. European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery, 2017, Volume: 53, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Amputation, Surgical; Aspirin; Clopidogrel; Constriction, Pathologic	2017
Prospective cohort study of type 2 diabetes and the risk of Parkinson's disease. Diabetes care, 2008, Volume: 31, Issue:10 Topics: Adult; Aged; Aspirin; beta Carotene; Body Mass Index; Cardiovascular Diseases; Cohort Studies; Diabe	2008
Aspirin in type 2 diabetes: is there any evidence base? BMJ (Clinical research ed.), 2008, Oct-16, Volume: 337 Topics: Aspirin; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Evidence-Based Medicine; Female; Humans;	2008
Aspirin for primary prevention of cardiovascular events in diabetes: still an open question. JAMA, 2008, Nov-12, Volume: 300, Issue:18 Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Platelet	2008
POPADAD trial. Time for a proper study of aspirin after a vascular event? BMJ (Clinical research ed.), 2008, Nov-19, Volume: 337 Topics: Aspirin; Diabetic Angiopathies; Humans; Periodicals as Topic; Peripheral Vascular Diseases; Platelet	2008
POPADAD trial. Don't stop taking aspirin. BMJ (Clinical research ed.), 2008, Nov-19, Volume: 337 Topics: Aspirin; Diabetic Angiopathies; Humans; Peripheral Vascular Diseases; Platelet Aggregation Inhibitor	2008
Aspirin attenuates cerebral ischemic injury in diabetic rats. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2009, Volume: 117, Issue:4 Topics: Animals; Aspirin; Blood Glucose; Brain Ischemia; Cerebral Infarction; Diabetes Mellitus, Experimenta	2009
Primary prevention of cardiovascular events in diabetes: is there a role for aspirin? Nature clinical practice. Cardiovascular medicine, 2009, Volume: 6, Issue:3 Topics: Antioxidants; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Diabetic Angiopathies; Humans; Pe	2009
[Factors that influence the implementation of the guidelines for aspirin use by diabetic patients in Israel]. Harefuah, 2008, Volume: 147, Issue:12 Topics: Adult; Aspirin; Diabetes Complications; Diabetes Mellitus; Diabetic Angiopathies; Female; Guidelines	2008
Very late drug-eluting stent thrombosis after nonsteroidal anti-inflammatory drug treatment despite dual antiplatelet therapy. The Canadian journal of cardiology, 2009, Volume: 25, Issue:4 Topics: Adult; Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Thrombosis; Cyclooxygenase Inh	2009
COX-1 sensitivity and thromboxane A2 production in type 1 and type 2 diabetic patients under chronic aspirin treatment. European heart journal, 2009, Volume: 30, Issue:10 Topics: Adult; Aged; Aspirin; Blood Platelets; C-Reactive Protein; Case-Control Studies; Cyclooxygenase 1; D	2009
A study of aspirin resistance in type 2 diabetes. Journal of the Indian Medical Association, 2008, Volume: 106, Issue:11 Topics: Aspirin; Cholesterol, LDL; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies	2008
Aspirin: not currently for primary prevention in diabetes. International journal of clinical practice, 2009, Volume: 63, Issue:6 Topics: Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Humans; Off-La	2009
Should aspirin be used for the primary prevention of cardiovascular disease in people with diabetes? The Medical journal of Australia, 2009, Sep-21, Volume: 191, Issue:6 Topics: Age Distribution; Age Factors; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascula	2009
The relation between platelet reactivity and glycemic control in diabetic patients with cardiovascular disease on maintenance aspirin and clopidogrel therapy. American heart journal, 2009, Volume: 158, Issue:5 Topics: Adult; Aged; Aspirin; Blood Glucose; Blood Platelets; Cardiovascular Diseases; Clopidogrel; Diabetes	2009
Do systemic risk factors impact invasive findings from virtual histology? Insights from the international virtual histology registry. European heart journal, 2010, Volume: 31, Issue:2 Topics: Aged; Aspirin; Coronary Artery Bypass; Coronary Artery Disease; Diabetic Angiopathies; Dyslipidemias	2010
Aspirin for primary prevention of cardiovascular disease? Drug and therapeutics bulletin, 2009, Volume: 47, Issue:11 Topics: Aspirin; Cardiovascular Diseases; Diabetic Angiopathies; Humans; Meta-Analysis as Topic; Off-Label U	2009
[Diabetes and a low dose of aspirin]. Nihon Shokakibyo Gakkai zasshi = The Japanese journal of gastro-enterology, 2009, Volume: 106, Issue:11 Topics: Aspirin; Diabetes Mellitus; Diabetic Angiopathies; Humans	2009
Aspirin for primary prevention of vascular disease in people with diabetes. BMJ (Clinical research ed.), 2009, Nov-06, Volume: 339 Topics: Aspirin; Cardiovascular Agents; Diabetic Angiopathies; Humans; Primary Prevention	2009
Aspirin is associated with reduced cardiovascular and all-cause mortality in type 2 diabetes in a primary prevention setting: the Fremantle Diabetes study. Diabetes care, 2010, Volume: 33, Issue:2 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Australia; Body Mass Index; Cardiovascular D	2010
Time to rethink aspirin in diabetes? BMJ (Clinical research ed.), 2009, Dec-23, Volume: 339 Topics: Aspirin; Diabetic Angiopathies; Humans; Hypoglycemic Agents	2009
Impact of chronic kidney disease on platelet function profiles in diabetes mellitus patients with coronary artery disease taking dual antiplatelet therapy. Journal of the American College of Cardiology, 2010, Mar-16, Volume: 55, Issue:11 Topics: Aged; Aspirin; Blood Platelets; Clopidogrel; Coronary Artery Disease; Cross-Sectional Studies; Diabe	2010
Adherence to vascular protection drugs in diabetic patients in Quebec: a population-based analysis. Diabetes & vascular disease research, 2010, Volume: 7, Issue:2 Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dia	2010
Aspirin as antiplatelet agent in diabetes. PROS-. European journal of internal medicine, 2010, Volume: 21, Issue:3 Topics: Aspirin; Diabetic Angiopathies; Evidence-Based Medicine; Humans; Platelet Aggregation Inhibitors; Th	2010
Aspirin as antiplatelet agent in diabetes: Cons. European journal of internal medicine, 2010, Volume: 21, Issue:3 Topics: Aspirin; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Hemorrhage; Humans; Platelet Aggregation	2010
Clinical determinants of aspirin resistance in diabetes. Diabetes research and clinical practice, 2010, Volume: 90, Issue:1 Topics: Albuminuria; Aspirin; Cohort Studies; Diabetic Angiopathies; Drug Resistance; Female; Glycated Hemog	2010
Long-term effects of cilostazol on the prevention of macrovascular disease in patients with type 2 diabetes mellitus. Diabetes research and clinical practice, 2011, Volume: 91, Issue:1 Topics: Aged; Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Cilostazol; Diabetes Mellitus, Ty	2011
Sex-specific differences in metabolic control, cardiovascular risk, and interventions in patients with type 2 diabetes mellitus. Gender medicine, 2010, Volume: 7, Issue:6 Topics: Aged; Angina Pectoris; Angioplasty, Balloon, Coronary; Antihypertensive Agents; Aspirin; Blood Gluco	2010
A problem of rigidity. Minnesota medicine, 2011, Volume: 94, Issue:1 Topics: Aspirin; Asthma; Biomedical Research; Chronic Disease; Comparative Effectiveness Research; Decision	2011
MN community measurement responds. Minnesota medicine, 2011, Volume: 94, Issue:1 Topics: Aspirin; Asthma; Biomedical Research; Comparative Effectiveness Research; Decision Support Technique	2011
Further ex vivo evidence supporting higher aspirin dosing in patients with coronary artery disease and diabetes. Circulation. Cardiovascular interventions, 2011, Apr-01, Volume: 4, Issue:2 Topics: Aspirin; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Dose-Response Re	2011
Aspirin resistance and platelet turnover: a 25-year old issue. Nutrition, metabolism, and cardiovascular diseases : NMCD, 2011, Volume: 21, Issue:8 Topics: Animals; Aspirin; Blood Platelets; Diabetic Angiopathies; Disease Models, Animal; Drug Resistance; H	2011
Letter by Santos et al regarding article, "Pharmacodynamic effects of different aspirin dosing regimens in type 2 diabetes mellitus patients with coronary artery disease". Circulation. Cardiovascular interventions, 2011, Volume: 4, Issue:4 Topics: Aspirin; Coronary Artery Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans;	2011
Primary prevention with aspirin in type 2 diabetic patients. Searching for the right spot. Circulation journal : official journal of the Japanese Circulation Society, 2012, Volume: 76, Issue:6 Topics: Aspirin; Blood Pressure; Cardiovascular Agents; Cerebrovascular Disorders; Diabetes Mellitus, Type 2	2012
The prevalence and factors associated with aspirin resistance in patients premedicated with aspirin. Acta cardiologica, 2012, Volume: 67, Issue:4 Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Diabetic Angiopathies; Drug Resistance; Female; Human	2012
Aspirin treatment hampers the use of plasma microRNA-126 as a biomarker for the progression of vascular disease. European heart journal, 2013, Volume: 34, Issue:44 Topics: Analysis of Variance; Arachidonic Acid; Aspirin; Biomarkers; Contraindications; Diabetes Mellitus, T	2013
Platelets, endothelium, and circulating microRNA-126 as a prognostic biomarker in cardiovascular diseases: per aspirin ad astra. European heart journal, 2013, Volume: 34, Issue:44 Topics: Aspirin; Contraindications; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Female; Humans; Male;	2013
Aspirin therapy in diabetes. Diabetes care, 2003, Volume: 26 Suppl 1 Topics: Aspirin; Diabetes Mellitus; Diabetic Angiopathies; Humans; Meta-Analysis as Topic; Quality Assurance	2003
Differential effect of aspirin on platelet aggregation in patients with coronary artery disease in relation with associated risk factors. Japanese heart journal, 2003, Volume: 44, Issue:1 Topics: Adult; Aged; Aspirin; Coronary Disease; Diabetic Angiopathies; Double-Blind Method; Humans; Hyperlip	2003
Management and short-term outcome of diabetic patients hospitalized for acute myocardial infarction: results of a nationwide French survey. Diabetes & metabolism, 2003, Volume: 29, Issue:3 Topics: Adrenergic beta-Antagonists; Aged; Aspirin; Body Mass Index; Diabetic Angiopathies; Female; France;	2003
Preventing diabetic retinopathy through control of systemic factors. Current opinion in ophthalmology, 2003, Volume: 14, Issue:6 Topics: Anticoagulants; Aspirin; Diabetic Angiopathies; Diabetic Retinopathy; Disease Progression; Female; G	2003
Aspirin for primary prevention of cardiovascular events in diabetes. Diabetes care, 2003, Volume: 26, Issue:12 Topics: Aspirin; Cardiovascular Diseases; Diabetic Angiopathies; Humans; Platelet Aggregation Inhibitors	2003
Aspirin therapy in diabetes. Diabetes care, 2004, Volume: 27 Suppl 1 Topics: Aspirin; Diabetes Mellitus; Diabetic Angiopathies; Female; Humans; Male; Platelet Aggregation Inhibi	2004
Intensive treatment of coronary artery disease in diabetic patients in clinical practice: results of the MITRA study. Acta diabetologica, 2003, Volume: 40 Suppl 2 Topics: Adrenergic beta-Antagonists; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Coronary Disea	2003
[Acetylsalicylic acid consumption in patients with diabetes mellitus]. Medicina clinica, 2004, Jan-31, Volume: 122, Issue:3 Topics: Adult; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Diabetic Angiopathies; Female; Humans; M	2004
[Underutilization of acetylsalicylic acid of cardiovascular prevention in patients with diabetes mellitus]. Medicina clinica, 2004, Jan-31, Volume: 122, Issue:3 Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Diabetic Angiopathies; Humans; Platelet Aggrega	2004
Coronary heart disease risk assessment in diabetes mellitus: comparison of UKPDS risk engine with Framingham risk assessment function and its clinical implications. Diabetic medicine : a journal of the British Diabetic Association, 2004, Volume: 21, Issue:3 Topics: Adult; Aged; Aspirin; Coronary Disease; Cross-Sectional Studies; Diabetic Angiopathies; Female; Huma	2004
[Therapeutic use of acetylsalicylic acid in diabetics]. Vnitrni lekarstvi, 2003, Volume: 49, Issue:12 Topics: Aspirin; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Fibrinolytic Agents; Humans; Platelet Agg	2003
Aspirin resistance and diabetic angiopathy: back to the future. Thrombosis research, 2004, Volume: 113, Issue:2 Topics: Aspirin; Blood Platelets; Diabetic Angiopathies; Drug Resistance; Humans; Platelet Aggregation; Thro	2004
Picotamide versus aspirin in diabetic patients with peripheral arterial disease: has David defeated Goliath? European heart journal, 2004, Volume: 25, Issue:20 Topics: Arteries; Aspirin; Diabetic Angiopathies; Humans; Peripheral Vascular Diseases; Phthalic Acids; Plat	2004
Underuse of aspirin therapy among patients with type 2 diabetes mellitus attending primary care in Greece. The European journal of general practice, 2004, Volume: 10, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Diabetes Mellitus,	2004
Aspirin for primary prevention in patients with diabetes mellitus. Family medicine, 2005, Volume: 37, Issue:2 Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; Diabetic Angiopathies; Female; Fibrinolytic Agents; G	2005
Coronary heart disease prevention in clinical practice: are patients with diabetes special? Evidence from two studies of older men and women. Heart (British Cardiac Society), 2005, Volume: 91, Issue:4 Topics: Aged; Antihypertensive Agents; Aspirin; Blood Pressure; Cholesterol; Coronary Disease; Diabetic Angi	2005
Prevalence of aspirin resistance in patients with type 2 diabetes. Acta diabetologica, 2005, Volume: 42, Issue:2 Topics: Aspirin; Blood Platelets; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Diabetic Angiopathies;	2005
[Assessment of the budgetary impact of treatment guidelines in type II diabetes mellitus in France]. Revue d'epidemiologie et de sante publique, 2005, Volume: 53 Spec No 1 Topics: Adolescent; Adult; Aged; Aspirin; Biguanides; Cerebrovascular Disorders; Coronary Disease; Cost-Bene	2005
Treatment disparities in the care of patients with and without diabetes presenting with non-ST-segment elevation acute coronary syndromes. Diabetes care, 2006, Volume: 29, Issue:1 Topics: Acute Disease; Adrenergic beta-Antagonists; Adult; Aspirin; Cardiac Catheterization; Clopidogrel; Co	2006
Antioxidative enzyme and glutathione S-transferase activities in diabetic rats exposed to long-term ASA treatment. Life sciences, 2006, Oct-04, Volume: 79, Issue:19 Topics: Animals; Antioxidants; Aspirin; Blood Glucose; Diabetes Mellitus, Experimental; Diabetic Angiopathie	2006
Insulin therapy is associated with platelet dysfunction in patients with type 2 diabetes mellitus on dual oral antiplatelet treatment. Journal of the American College of Cardiology, 2006, Jul-18, Volume: 48, Issue:2 Topics: Aged; Aspirin; Clopidogrel; Coronary Disease; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Drug	2006
Aspirin and clopidogrel resistance in patients with diabetes mellitus. European heart journal, 2006, Volume: 27, Issue:23 Topics: Aspirin; Clopidogrel; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; D	2006
An appraisal of aspirin therapy in diabetes. Current diabetes reports, 2006, Volume: 6, Issue:6 Topics: Adult; Aspirin; Coronary Disease; Diabetic Angiopathies; Drug Resistance; Humans; Platelet Aggregati	2006
TNF-alpha -308G>A polymorphism modulates cytokine serum concentrations and macrovascular complications in diabetic patients on aspirin. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2007, Volume: 115, Issue:5 Topics: Aged; Aspirin; Cerebrovascular Disorders; Coronary Disease; Cytokines; Diabetes Mellitus, Type 2; Di	2007
AHA/ADA vs. ESC/EASD recommendations on aspirin as a primary prevention strategy in people with diabetes: how the same data generate divergent conclusions. European heart journal, 2007, Volume: 28, Issue:16 Topics: Adult; Aged; Aspirin; Data Collection; Data Interpretation, Statistical; Diabetic Angiopathies; Euro	2007
By the way, doctor. Must I take aspirin? Harvard health letter, 2007, Volume: 32, Issue:9 Topics: Aspirin; Attitude of Health Personnel; Colitis, Ulcerative; Diabetic Angiopathies; Female; Humans; M	2007
Aspirin and mortality in patients with diabetes sustaining acute coronary syndrome. Diabetes care, 2008, Volume: 31, Issue:2 Topics: Acute Coronary Syndrome; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Cohort Studies; Di	2008
Aspirin resistance and diabetes mellitus. Diabetologia, 2008, Volume: 51, Issue:3 Topics: Aspirin; Blood Platelets; Diabetes Complications; Diabetic Angiopathies; Drug Resistance; Humans; Pl	2008
Should we prescribe statin and aspirin for every diabetic patient? Is it time for a polypill? Diabetes care, 2008, Volume: 31 Suppl 2 Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Coronary Disease; Diabetes Complications	2008
Should we be more aggressive in the therapy against cardiovascular risk factors? Should we prescribe statin and aspirin for every diabetic patient, or is it time for a polypill? Diabetes care, 2008, Volume: 31 Suppl 2 Topics: Aspirin; Cardiovascular Diseases; Clinical Trials as Topic; Diabetic Angiopathies; Drug Therapy, Com	2008
[Acetylsalicylic acid hypersensitivity in a patient with coronary artery disease and insulin-dependent diabetes mellitus]. Kardiologia polska, 2008, Volume: 66, Issue:1 Topics: Angioplasty, Balloon, Coronary; Aspirin; Coronary Angiography; Coronary Artery Disease; Desensitizat	2008
4 ways to save your heart. Diabetes forecast, 2008, Volume: 61, Issue:2 Topics: Aspirin; Blood Glucose; Blood Pressure; Diabetes Mellitus; Diabetic Angiopathies; Heart; Humans; Lip	2008
Antithrombotic therapy in peripheral arterial disease. Cardiology clinics, 2008, Volume: 26, Issue:2 Topics: Anticoagulants; Aspirin; Atherosclerosis; Cilostazol; Clopidogrel; Comorbidity; Diabetic Angiopathie	2008
Comment on: DiChiara et al. (2007) The effect of aspirin dosing on platelet function in diabetic and nondiabetic patients: an analysis from the aspirin-induced platelet effect (ASPECT) study: Diabetes 56:3014-3019, 2007. Diabetes, 2008, Volume: 57, Issue:5 Topics: Aged; Aspirin; Blood Platelets; Coronary Disease; Diabetic Angiopathies; Female; Humans; Male; Middl	2008
Control of cardiovascular risk factors and use of aspirin in diabetic patients remain elusive. Southern medical journal, 2008, Volume: 101, Issue:6 Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Albuminuria; Aspirin; Blood Pressure; Chol	2008
[Use of disaggregants in treating diabetic retinopathy]. Oftalmologicheskii zhurnal, 1984, Issue:7 Topics: Ascorbic Acid; Aspirin; Calcium Dobesilate; Diabetic Angiopathies; Diabetic Retinopathy; Dipyridamol	1984
[Effect of acetylsalicylic acid and dipyridamole on the microcirculatory state of diabetes mellitus patients based on biomicroscopy and rheography data]. Vrachebnoe delo, 1983, Issue:11 Topics: Adolescent; Adult; Aged; Aspirin; Chronic Disease; Conjunctiva; Diabetic Angiopathies; Dipyridamole;	1983
[Several methods of treatment of diabetes mellitus and its complications]. Terapevticheskii arkhiv, 1982, Volume: 54, Issue:3 Topics: Acid-Base Equilibrium; Adult; Aspirin; Blood Viscosity; Diabetes Mellitus; Diabetic Angiopathies; Di	1982
Which diabetic patients should be taking aspirin? BMJ (Clinical research ed.), 1995, Sep-09, Volume: 311, Issue:7006 Topics: Aspirin; Diabetes Mellitus; Diabetic Angiopathies; Humans; Platelet Aggregation Inhibitors; Risk Fac	1995
Prevention of vascular events in diabetes mellitus: which "antithrombotic" therapy? Diabetologia, 1996, Volume: 39, Issue:11 Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetic Angiopathies; Fibrinolytic Agents	1996
Assessing the evidence on aspirin in diabetes mellitus. Gemini or Libra; lumping or splitting; surrogate or hard; low or high; interventionist or nihilist. Diabetologia, 1996, Volume: 39, Issue:11 Topics: Aspirin; Cardiovascular Diseases; Cerebrovascular Disorders; Diabetes Complications; Diabetic Angiop	1996
Progression of distal symmetric polyneuropathy during diabetes mellitus: clinical, neurophysiological, haemorheological changes and self-rating scales of patients. European neurology, 1997, Volume: 37, Issue:2 Topics: Adolescent; Adult; Aged; Aspirin; Blood Glucose; Blood Viscosity; Diabetes Mellitus, Type 1; Diabete	1997
Outcome of unstable angina in patients with diabetes mellitus. Diabetic medicine : a journal of the British Diabetic Association, 1997, Volume: 14, Issue:3 Topics: Adrenergic beta-Antagonists; Aged; Angina, Unstable; Angioplasty; Aspirin; Calcium Channel Blockers;	1997
Aspirin therapy in diabetes mellitus. Diabetologia, 1997, Volume: 40, Issue:7 Topics: Aspirin; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Gastrointestin	1997
Coronary artery disease and diabetes. Heart (British Cardiac Society), 1997, Volume: 78, Issue:6 Topics: Aspirin; Coronary Angiography; Coronary Disease; Diabetic Angiopathies; Female; Humans; Hypolipidemi	1997
[Should one prescribe aspirin for all diabetics?]. Diabetes & metabolism, 1997, Volume: 23, Issue:6 Topics: Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Diabetic Angiopathies; Humans; Platelet Aggrega	1997
Management of patients with diabetes after heart attack: a population-based study of 1982 patients from a heart disease register. Australian and New Zealand journal of medicine, 1998, Volume: 28, Issue:3 Topics: Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aspirin; Austral	1998
Physical activity, dyspnea, and chest pain before and after coronary artery bypass grafting in relation to a history of diabetes. Diabetes care, 1998, Volume: 21, Issue:10 Topics: Activities of Daily Living; Aspirin; Chest Pain; Coronary Artery Bypass; Diabetic Angiopathies; Dipy	1998
Aspirin usage in a large teaching hospital diabetes clinic setting. Diabetic medicine : a journal of the British Diabetic Association, 1999, Volume: 16, Issue:7 Topics: Adult; Aged; Aged, 80 and over; Aspirin; Australia; Diabetes Mellitus, Type 1; Diabetes Mellitus, Ty	1999
Enhanced platelet aggregation, high homocysteine level, and microvascular disease in diabetic muscle infarctions: implications for therapy. Endocrine, 1999, Volume: 11, Issue:1 Topics: Adult; Aspirin; Diabetes Mellitus, Type 1; Diabetic Angiopathies; Female; Folic Acid; Hematinics; Ho	1999
The salicylate metabolite gentisic acid, but not the parent drug, inhibits glucose autoxidation-mediated atherogenic modification of low density lipoprotein. FEBS letters, 2000, Mar-17, Volume: 470, Issue:1 Topics: Arteriosclerosis; Aspirin; Cells, Cultured; Diabetic Angiopathies; Endothelium, Vascular; Gentisates	2000
Effect of naftidrofuryl on platelet aggregation in plasma from aspirin treated patients: an in vitro study. Clinical hemorheology and microcirculation, 2000, Volume: 22, Issue:3 Topics: Aged; Aged, 80 and over; Aspirin; Diabetic Angiopathies; Drug Interactions; Female; Humans; Male; Mi	2000
The Hypertension Optimal Treatment Study: what did it give us? Current hypertension reports, 1999, Volume: 1, Issue:4 Topics: Aged; Aspirin; Blood Pressure; Diabetic Angiopathies; Fibrinolytic Agents; Humans; Hypertension; Mid	1999
Aspirin in diabetes: beware of retinopathy. Archives of internal medicine, 2000, Oct-23, Volume: 160, Issue:19 Topics: Aspirin; Contraindications; Diabetic Angiopathies; Diabetic Retinopathy; Humans; Platelet Aggregatio	2000
Diabetes mellitus with left transverse sinus thrombosis and right transverse sinus aplasia. Diabetes research and clinical practice, 2001, Volume: 51, Issue:1 Topics: Aged; Aspirin; Cerebral Angiography; Cranial Sinuses; Diabetes Mellitus, Type 2; Diabetic Angiopathi	2001
Aspirin therapy in diabetes is underutilized. Diabetes care, 2001, Volume: 24, Issue:2 Topics: Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabetic Angiopathies; Humans	2001
Aspirin use among adults with diabetes: estimates from the Third National Health and Nutrition Examination Survey. Diabetes care, 2001, Volume: 24, Issue:2 Topics: Adult; Albuminuria; Angina Pectoris; Aspirin; Cardiovascular Diseases; Diabetes Complications; Diabe	2001
[Cardiovascular diseases in diabetes]. Praxis, 2001, Dec-20, Volume: 90, Issue:51-52 Topics: Anticholesteremic Agents; Antihypertensive Agents; Aspirin; Clinical Trials as Topic; Coronary Disea	2001
Low aspirin use in diabetics. Saudi medical journal, 2002, Volume: 23, Issue:4 Topics: Adult; Aged; Aspirin; Diabetic Angiopathies; Female; Humans; Male; Middle Aged; Risk Factors	2002
Aspirin use and counseling about aspirin among patients with diabetes. Diabetes care, 2002, Volume: 25, Issue:6 Topics: Aged; Aspirin; Cardiovascular Diseases; Diabetes Mellitus; Diabetic Angiopathies; Female; Health Kno	2002
[Inhibitors of platelet aggregation in the therapy of arteriosclerosis obliterans]. Zeitschrift fur die gesamte innere Medizin und ihre Grenzgebiete, 1979, May-15, Volume: 34, Issue:10 Topics: Arteriosclerosis Obliterans; Aspirin; Diabetic Angiopathies; Dipyridamole; Humans; Platelet Aggregat	1979
Aspirin: new uses for an old drug. Comprehensive therapy, 1979, Volume: 5, Issue:10 Topics: Aspirin; Bartter Syndrome; Diabetic Angiopathies; Ductus Arteriosus, Patent; Humans; Myocardial Infa	1979
Altered platelet function in diabetes mellitus. Diabetes, 1976, Volume: 25, Issue:2 SUPPL Topics: Adenosine Diphosphate; Adult; Arachidonic Acids; Aspirin; Blood Platelets; Collagen; Cyclooxygenase	1976
Increased platelet aggregation in early diabetus mellitus. Annals of internal medicine, 1975, Volume: 82, Issue:6 Topics: Adenosine Diphosphate; Administration, Oral; Aspirin; Collagen; Diabetes Mellitus; Diabetic Angiopat	1975
[Treatment of acute manifestation of hemichorea with aspirin. A case report]. Acta medica Austriaca, 1991, Volume: 18, Issue:4 Topics: Aged; Aged, 80 and over; Anesthesia, General; Aspirin; Brain Ischemia; Carotid Stenosis; Chorea; Cor	1991
Effect of antiplatelet drug therapy on the retinal vascular pattern in experimental diabetes mellitus. Canadian journal of ophthalmology. Journal canadien d'ophtalmologie, 1990, Volume: 25, Issue:7 Topics: Animals; Aspirin; Collagen; Diabetes Mellitus, Experimental; Diabetic Angiopathies; Dipyridamole; Dr	1990
[Study of plasma beta thromboglobulin level induced by heparin in diabetic patients]. Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics, 1988, Volume: 25, Issue:5 Topics: Adult; Aged; Aspirin; beta-Thromboglobulin; Diabetes Mellitus; Diabetic Angiopathies; Female; Hepari	1988
Trial of repeated low-dose aspirin in diabetic angiopathy. Blood, 1986, Volume: 68, Issue:4 Topics: Adenosine Triphosphate; Adult; Arachidonic Acid; Arachidonic Acids; Aspirin; Blood Platelets; Collag	1986
[Effect of acetylsalicylic acid on thrombocyte function in patients with diabetes mellitus (review of the literature)]. Vrachebnoe delo, 1987, Issue:1 Topics: Aspirin; Blood Platelets; Diabetes Mellitus; Diabetic Angiopathies; Humans	1987

aspirin and Diabetic Angiopathies